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THE ROLE OF PKC-EPSILON IN MODELS OF ALCOHOL- AND TOXIN-
INDUCED LIVER DISEASE 
J.Phillip Kaiser 
December 17, 2009 
Alcoholic liver disease (ALD) is a serious concern for the world's 
population. It is one of the leading causes of death and is also a huge economic 
burden. The biochemical mechanisms responsible for ALD are incompletely 
understood, therefore there is no FDA approved therapy to treat or reverse liver 
damage caused by alcohol exposure. Whereas the mechanisms behind ALD are 
poorly understood, the disease progression is well known. The first pathological 
step of ALD is steatosis followed by inflammation and necrosis; if the insult(s) 
responsible for the previous pathologies persists, fibrosis and cirrhosis can then 
develop. In previous experimental studies, preventing alcohol-induced steatosis 
can protect against further stages of liver damage; thus, understanding the 
mechanisms responsible for ethanol-induced steatosis may result in a therapy to 
treat ALD. Previous studies have shown that protein kinase-c epsilon (PKC£) 
contributes to steatosis owing to a non-alcoholic high fat diet. However, the role 
of PKC£ in alcohol-induced fatty liver is not yet known. Therefore, the goal of this 
work was to investigate the role of PKC£ in not only steatosis, but also in later 
stages of liver disease (i.e. steatohepatitis and fibrosis). It was determined in 
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both acute and chronic mouse models of ethanol exposure that PKC£ plays a 
causal role in steatosis owing to ethanol. Surprisingly, blocking steatosis had no 
apparent protective effect on inflammation and necrosis in the chronic model, 
which implies that these pathologies may have mechanistic distinctions. Lastly, it 
was shown that PKC£ plays a pivotal role in the development of fibrosis caused 
by chronic exposure to carbon tetrachloride (CCI4). In summary, it appears that 
PKC£ plays a causal role in the early (steatosis) and late (fibrosis) stages of liver 
disease. The inhibition of PKC£ could therefore result in a viable therapeutic 
means of preventing ALD. 
vi 
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A. Background and Rationale for Study 
1. Why ALD is bad 
Alcoholic liver disease (ALD) is a serious medical concern for the world's 
population. Liver damage owing to alcohol is the most common form of liver 
disease. Furthermore, ALD is one of the leading causes of death in the world,1 
affecting millions of people per year. For example, ALD is the fourth leading 
cause of death among urban males.2 ALD also poses a huge economic burden. 
From 1985 to 1992, it is estimated that over $148 billion was spent to treat 
people with ALD in the US alone.3 Despite the severity of ALD to the world's 
population, there is no FDA-approved therapy to treat or reverse the disease due 
to the mechanisms behind ALD being poorly understood. 
2. Current clinical treatment of ALD 
Currently, the clinical treatment of ALD focuses on abstinaining from 
drinking alcohol, treating decompensation, or transplanting the damaged liver. 
Abstinence from alcohol is the most obvious treatment in preventing ALD. In 
fact, numerous studies have shown the effectiveness of abstinence.4 
Specifically, in patients with alcoholic cirrhosis, abstinence improved the survival 
rate by almost 50%.5 However, there is a very high rate of recidivism among 
alcoholic patients, thus making abstinence a rather unrealistic approach in 
treating ALD. Another means of combating ALD is treating the decompensation 
associated with the disease. There are many side effects of ALD, such as 
ascites, portal hypertension, and hepatorenal syndrome. It is these secondary 
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effects of ALD that usually lead to the death of patients with ALD.4 Treating 
these secondary effects can prolong the life of ALD patients, but is only palliative. 
One of the most effective ways to treat ALD is liver transplantation. However, 
there are many barriers to this treatment, such as organ shortage, costs, and the 
ethical issue that people who have damaged their liver by abusing alcohol do not 
deserve a transplanted one.4 Furthermore, in order to be considered for a liver 
transplant, most clinics require alcoholics to abstain from drinking for six months, 
a task that proves to be impossible for most. Therefore, the finding of an 
appropriate therapy is critical to prevent alcohol-induced liver damage. 
There are many emerging drug therapies to treat ALD. These drugs 
potentially treat ALD by preventing the immune response and proinflammatory 
cytokine release caused byalcohol.4 Some examples of these drugs are 
corticosteroids, pentoxifylline, and infliximab. These drugs have had some 
success in the clinics however they are not without drawbacks. For example, 
corticosteroids can only be used in the later stages of ALD, such as cirrhosis.4 
Furthermore, corticosteroids have been shown to increase the risk of infections 
which could lead to death in some cases.4 Unfortunately, most drugs currently 
employed to treat alcoholics with liver disease, have similar drawbacks (e.g. 
increased risk of infection) thus increasing the urgency to develop better 
therapies that not only have fewer devastating side effects but can be used 
before later stages of ALD ensue. 
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3. Mechanisms of ALD are poorly understood 
The therapies discussed previously (Chapter I, section A2) are only 
partially effective. Therefore, there is more focus on understanding the 
biochemical mechanisms behind the development and progression of ALD. 
Whereas the mechanisms behind ALD are poorly understood, the disease 
progression is well understood. The first pathological change associated with 
ALD is steatosis, also known as fatty liver. If the abuse of alcohol continues, 
steatohepatitis (necrosis and inflammation) can occur followed by fibrosis and 
cirrhosis. Once the mechanisms behind these various pathologies are better 
understood, it is more likely that a viable therapeutic target to treat ALD will be 
identified. This Introduction will focus on the early pathologies of ALD that are 
known to be readily reversible and the histology associated with each, as well as 
the mechanisms hypothesized to be responsible for each respective one. 
B. Natural History of Alcoholic Liver Disease 
1. Alcoholic Steatosis (Fatty Liver) 
The first pathological change associated with ALD is steatosis. Steatosis 
is a very common result of drinking alcohol, occurring in nearly 90% of people 
that consume alcohol and is rapidly (a few days) reversible with even the most 
extreme cases of fatty liver disappearing after three weeks of abstaining from 
alcohol.6,7 Steatosis is characterized by fat infiltration in the liver that can be 
classified as either macrovesicular or microvesicular. Macrovesicular steatosis is 
defined as having one large fat droplet per hepatocyte and lateral displacement 
of the nucleus whereas microvesicular is classified as many small fat droplets per 
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hepatocyte.8 Whereas steatosis was once thought to an inert pathology of ALD, 
more recent evidence has indicated that blunting or blocking steatosis could help 
prevent the progression of ALD.9, 10, 11 As the liver accumulates fat, metabolic 
changes occur that sensitize the liver to further injury. Furthermore, the higher 
the degree of hepatic steatosis, the more suspectible a liver is to further stages of 
liver damage.9 Therefore, understanding the biochemical mechanisms by which 
alcohol is causing steatosis may be important in finding a means to prevent the 
later stages of ALD. 
It has long been established that the metabolism of alcohol directly 
contributes to hepatic fat accumulation caused by this drug. Specifically, the 
metabolism of alcohol increases the ratio of NADH:NAD+ within the cell, which 
subsequently inhibits ~-oxidation of fatty acids in the liver. Alcohol metabolism 
also increases the rate of esterification of fatty acids,12 These changes in fatty 
acid flux caused by ethanol metabolism subsequently lead to an accumulation of 
hepatic lipids. However, previous studies suggest that alcohol metabolism may 
not be the only causal factor for steatosis caused by ethanol. Specifically, many 
pharmacologic agents and genetic manipulations (e.g. knockouts) have been 
shown to block hepatic steatosis in rodent models of enteral alcohol exposure. 
For example, mice deficient in prooxidant-producing enzymes (e.g., NADPH 
oxidase and iNOS)13, 14 or LPS binding/signaling molecules (e.g., CD14, TLR4, 
and LBP), all have less steatosis in response to alcohol compared with wild-
types. 15.17 However, these pharmacologic/genetic changes that protected 
against steatosis had no apparent effect on alcohol metabolism, which implies 
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that the shift in the NADH redox state still occurs. It is therefore likely alcohol 
metabolism is not the sole causal factor in ethanol-induced steatosis. 
Impaired insulin signaling may also increase hepatic lipid accumulation 
caused by alcohol exposure. Insulin is a hormone with the main function of 
maintaining glucose homeostasis by causing organs (e.g. liver, muscle, etc.) to 
take up glucose from the blood. Once inside the cells of an organ, the glucose is 
metabolized (Le. glycolysis) to provide the cell with energy. Insulin resistance 
refers to the situation where due to impairment of insulin signaling (see Chapter 
1, section 4C for more detail), normal amounts of insulin are no longer sufficient 
to cause transportation of glucose into a cell. This loss of insulin sensitivity can 
lead to hyperglycemia, bacterial infection, and impaired lipid metabolism.18 
It is known that chronic and acute ethanol exposure cause hepatic insulin 
resistance in animal models.19 Furthermore, insulin resistance is a known risk 
factor for the development of ALD in humans.2o The effect of impaired insulin 
signaling on hepatic lipid accumulation is well-documented, especially in non-
alcoholic fatty liver disease (NAFLD; see 18 for review). Whereas less well-
characterized, it is likely that insulin resistance similarly affects lipid metabolism 
in alcohol-induced liver disease. Indeed, recent work from this group has shown 
that the insulin-sensitizing drug, metformin, blocks fatty liver caused by ethanol 
exposure, supporting a causal link between insulin resistance and hepatic 
steatosis after ethanol exposure.21 
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2. Alcoholic Steatohepatitis (ASH) 
The next stage of ALD is steatohepatitis, which like steatosis is also 
reversible upon abstinence from drinking alcohol. However, the reversion of 
steatohepatitis requires several weeks to months unlike steatosis which usually 
only requires days to revert to normal.22 The histological characteristics of 
steatohepatitis are macro- and microvesicular steatosis along with a robust 
infiltration of neutrophils as well as hepatocyte degeneration, ballooning, and 
oncotic necrosis, as well as hepatocyte apoptosis.23 While steatohepatitis is 
reversible, this stage of ALD is considered to be a rate-limiting step in the 
development of cirrhosis, as liver-related morbidity and death can occur in people 
with steatohepatitis.24,25 
One of the prevailing hypotheses in the field of hepatology research is the 
"two-hit" hypothesis also known as "sensitization", which suggests that hepatic 
steatosis is not an inert pathology and may actually sensitize the liver to a 
second insult.9 For example, a previous study determined that a steatotic liver is 
more susceptible to endotoxtin- or cytokine-induced liver damage.26, 27 One 
possible explanation could be that upon the development of steatosis, the liver 
undergoes cellular changes which sensitize the hepatocytes to further damage.28 
One such cellular change responsible for the sensitization effect could be the 
decrease in peroxisome proliferators-activated receptors associated with liver 
inury.29.31 
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Alcohol can not only sensitize the liver to further injury by causing 
steatosis, but can also directly sensitize liver cells to inflammatory stimuli. For 
example, previous studies have determined that alcohol administration switches 
the function of TNFa from proproliferative to proapoptotic and that hepatocytes 
over expressing CYP2E1 become more sensitive to TN Fa-induced cell death 
after alcohol exposure.26, 32, 33 The "two-hit" or "sensitization" hypothesis is just 
one mechanistic example by which alcohol may be causing inflammation. 
Another mechanism thought to playa causal role in inflammation is a 
concept referred to as 'priming'. In a previous study by Deaciuc et aI., it was 
determined that chronic low-dose LPS can only cause an inflammatory response 
in the presence of alcohol.34 In that model, alcohol exposure "primes" 
inflammatory cells to be activated by LPS. In support of this hypothesis, higher 
levels of the proinflammatory mediator TNFa are produced from monocytes 
isolated from patients with alcoholic hepatitis than in monocytes from drinkers 
without liver disease.35 Alcohol exposure also increases the production of many 
proinflammatory cytokines/chemokines besides TNFa, such as IL-6, IL-8, and 
MCP-1, while at the same time, decreasing anti-inflammatory cytokines.36-38 The 
increase in cytokines/chemokines along with other mediators of inflammation 
(e.g. cytokine receptors) not only cause liver damage but also the systemic 
effects of ALD as we11.35, 39 
The role of primed inflammatory cells by ethanol has also been well 
investigated. For example, one specific type of liver cell that produces 
proinflammatory cytokines are Kupffer cells, the resident macrophages of the 
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liver. In a study completed by Dr. Thurman's group using a chronic model of 
ethanol exposure, mice were treated with gadolinium chloride (GdCh), a 
chemical that is directly toxic to Kupffer cells. GdCh prevented liver injury owing 
to chronic ethanol most likely due to the inability of Kupffer cells to produce 
mediators of inflammation.40 
Priming and sensitization are both valid hypotheses by which ethanol can 
cause inflammation. These two scenarios, priming and sensitization, can be 
considered a series of events that occur during the progression of alcohol-
induced liver injury. Specifically, alcohol primes inflammatory cells (e.g. Kupffer 
cells) to release mediators of inflammation (TNFa, IL-6, etc) that cause 
hepatoxicity in liver cells that have been sensitized by ethanol. Many studies 
support this concept, and the role of inflammatory cytokines in hepatic 
inflammation has been extensively researched. For example, TNFR1 knockout 
mice are protected against chronic ethanol-induced inflammation.41 Therefore, a 
suitable therapy in preventing ethanol-induced inflammation may need to target 
both priming and sensitization owing to alcohol exposure. 
3. Fibrosis 
Fibrosis is considered to be a wound healing process characterized by not 
only the previously mentioned pathologies (Le. steatosis, inflammation, and 
necrosis); but also by accumulation of extracellar matrix proteins (ECM) 
(collagen, fibrin, etc) in the extracellular space of the liver, which then scars the 
liver.42 Although not as readily reversible as steatosis and steatohepatitis 
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requiring much more time (months to years), fibrosis has been shown to revert to 
a normal liver if the underlying cause (e.g. hepatitis virus C inftecion) is 
effectively treated.43 
One possible mechanism of hepatic fibrosis is an increase in production of 
ECM (e.g. collagen, fibrin, laminin, etc.) increasing accumulation of ECM. When 
a liver transitions to a profibrotic state, hepatic stellate cells become activated, 
usually by profibrotic cytokines (e.g. TGF~-1) or transcription factors like Foxf1 
and JunO.42 Upon activation, stellate cells transform to myofibroblats which 
synthesize and secrete ECM. In support of the role for stellate cell activation in 
causing fibrosis, inhibiting transcription factors that activate stellate cells, 
protected against fibrosis in various models. For example in a mouse model of 
CCl4-induced fibrosis, JunO knockout mice had fewer activated stellate cells and 
less fibrosis compared to wild-type mice.44 
Another mechanism responsible for fibrosis is a decrease in the 
degradation of ECM that are secreted by stellate cells. A key determinant in the 
development of fibrosis is the balance between collaganeses (e.g. MMPs) that 
degrade ECM and their inhibitors (e.g. TIMPs).45 In support of this balance, the 
inhibition of TIMPs has been shown to partially protect against CCl4-induced 
fibrosis.46 Furthermore, mechanisms that induce the degradation of ECM have 
also been shown to playa role in preventing fibrosis; one such mechanism is the 
plasminogen activating system. The activation of plasminogen by uPAItPA to 
plasmin is a crucial step in preventing fibrosis as plasmin has been shown to 
directly degrade ECM-type proteins such as fibrin and laminin and indirectly 
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activate MMPs.47-50 Therefore, inhibitors of the plasminogen activating system 
may playa causal role in hepatic fibrosis. One such inhibitor PAI-1, prevents the 
conversion of plasminogen to plasmin by inhibiting the activity of uPA and tPA 
and has been shown to playa causal role in bile duct ligation-induced hepatic 
fibrosis by impairing matrix degradation.51 
4. Cirrhosis and Hepatocellular Carcinoma 
If the insult(s) responsible for liver disease continue beyond fibrosis, 
cirrhosis can develop. Cirrhosis is considered to be an advanced stage of 
fibrosis; unlike fibrosis, cirrhosis is not reversible. Cirrhosis is characterized by 
more extensive scarring than fibrosis as well as altered liver parenchyma with 
septae and nodule formation, as well as distorted hepatic blood flow. 42• 52 Once 
cirrhosis develops, the result will most likely be mortality without a liver 
transplant. 52 Death of the patient is not due to the actual cirrhosis but due to the 
secondary complications of the disease, such as hepatorenal syndrome and/or 
portal hypertension.4 Some patients are able to maintain compensated cirrhosis 
(i.e. stable cirrhotics), but the risk for the development of hepatocellular 
carcinoma increases -20-fold due to preexistence of cirrhosis.53 The survival 
rate for a person inflicted with hepatocellular carcinoma is essentially nil.54 This 
high mortality rate of cirrhosis further emphasizes the need for a therapy that can 
prevent the progression of ALD before cirrhosis develops. 
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C. PKCs 
Protein Kinases C (PKC) comprises~ 11 isozymes of a family of 
serine/threonine kinases that a playa role in a variety of cellular signaling 
pathways.55 The PKC superfamily is comprised of three subfamilies (classical, 
conventional, and atypical) classified by their requirements for activation. The 
classical subfamily (e.g. PKCs a and ~1) is activated by calcium, diacylglycerol 
(DAG) and phospholipids. The novel family (PKCs 11 and £) is not regulated by 
calcium but is activated by DAG and fatty acids instead. Finally, the last class is 
the atypical class, which require neither DAG nor calcium to become activated.56 
Although the subfamilies differ in their needs for activation, the general response 
once activated is quite similar. Upon binding of a cofactor (e.g. DAG, calcium, 
etc.) to the regulatory domain of the enzyme, the protein migrates to the 
membrane. Prior to this membrane interaction, there is a pseudosubstrate that is 
present-in the catalytic region of the enzyme, maintaining the inactivity of the 
PKC. Once the enzyme is recruited to the membrane, the pseudosubstrate is 
released from the catalytic site and the PKC is then activated.55 
The PKC family plays various biological roles, such as desensitizing 
receptors, regulating cell growth, and mediating immune responses. Whereas 
most PKC isozymes are expressed in various tissues and have multiple roles, 
some may be distributed in certain tissues and have unique roles in their 
respective tissue location.57 For example, PKCy is located primarily in the brain 
and plays a role in regulating the membrane structure of the central nervous 
system. However, isozymes like a and ~1 are expressed in multiple tissues (e.g. 
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liver, muscles, etc) and playa role in numerous physiological processes.57 
One pathway that almost all PKCs regulate is the insulin signaling.58 
Whereas some isotypes of PKC (e.g. 0) have a positive effect on the insulin 
signaling cascade, most PKCs impair insulin signaling. The binding of insulin to 
its receptor actives an intrinsic tyrosine kinase that phosphorylates the insulin 
receptor substrates (IRS). Upon tyrosine phosphorylation, signaling molecules 
like PI3K are recruited and become activated and through a series of 
downstream signaling events induce the physiological actions (e.g. cellular 
uptake of glucose, glucose metabolism, etc.) of insulin to maintain glucose 
homeostatis.58 PKCs disrupt insulin signaling by phosphorylating serine residues 
on IRS proteins, which then increases gluconeogenesis and the subsequent 
insulin resistance. 59 
D. PKCE 
One example of a PKC that induces insulin resistance is PKCE. PKCE is a 
novel isotype, found in many organs, including the liver, and plays a diverse role 
in many cellular processes. Interestingly, many of the roles of PKCE coincide 
with mechanisms thought to playa part in the different pathologies (steatosis, 
steatohepatitis, and fibrosis) of ALD. For example, PKCE induces hepatic and 
muscular insulin resistance by increasing the serine phosphorylation of IRS-2, 
causing a decrease in tyrosine phosphorylation leading to impaired glycogen 
production and an increase in glucose production (see Figure 1.1 for detailed 
mechanism).18 Given this role of PKCE in insulin resistance, a known risk factor 
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of steatosis, it is therefore possible that this kinase could also plays a role in 
ethanol-induced steatosis. 
One of the major mechanisms by which chronic ethanol is hypothesized to 
cause inflammation is by priming macrophages (e.g. Kupffer cells) to release 
mediators that contribute to hepatic inflammation (see Chapter 1, section B2 for 
detailed mechanism). The killing of Kupffer cells via GdCb partially prevents 
alcohol-induced liver injury, further supporting the role of macrophages in 
inflammation owing to ethanol.4o PKC£ has also been shown to playa critical 
role in the priming of proinflammatory cells as macrophages from PKC£ knockout 
mice have an impaired response to LPS, characterized by a decrease in the 
amount of proinflammatory cytokines that are released.6o Therefore as PKC£ is 
known to prime macrophages, it may be possible that PKC£ plays a casual role 
in inflammation owing to chronic ethanol via the activation of Kupffer cells and 
the subsequent secretion of proinflammatoy mediators like TNFa., that are 
directly toxic to hepatocytes. 
The next pathological step of ALD proceeding steatohepatitis is fibrosis, 
the last reversible phase of liver disease preceding cirrhosis. Whereas fibrosis or 
"remodeling" happens in many tissues besides the liver, such as bloods vessels 
(Le. atherosclerosis) and kidneys (Le. glomuleronephritis), the mechanisms 
behind fibrosis are potentially similar from organ to organ. For example, a major 
determinant in the transition of any organ to a profibrotic state is the activation 
and conversion of a cell type (e.g stellate cells in liver) to a myofibroblast, which 
then secrete ECM. Although the role of PKC£ in regulating myofibroblast 
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conversion and ECM secretion has not been directly tested in the liver, there is 
literature support for PKCe:-dependent control of these parameters in other 
organs. For example, the knockdown of PKCe: blunted lung fibrosis in patients 
with systemic sclerosis by decreasing the number of myofibroblasts.61 
E. Experimental Models of ALD 
To investigate the role of PKCe: in various stages of ALD, a number of 
different animal models must be used to produce the pathological features 
observed in the human disease. There are many types of animal models of ALD, 
such as rodents, pigs, and nonhuman primates. For example, nonhuman 
primate models of ALD are good paradigms, due to physiological similarities to 
humans, to provide validation of a therapy that has been shown to be effective in 
treating ALD in rodent or other small animal models. However, the downside of 
using nonhuman primates to model ALD is the large expansive costs of their 
employment and the significant amount of time (months to years) these models 
need to cause a pathology of interest. Rodent models are advantageous due to 
the relatively inexpensive costs and the short length of time required to produce 
gross morphological changes observed in ALD. Mice are particularly useful 
because of the ability to genetically-alter them (knockout mice) to study a 
mechanism of interest. 
The first animal model used in this dissertation was a mouse model of 
acute ethanol exposure which consists of a single bolus dose of ethanol. This 
model is advantageous as it is relativity quick compared to other models and 
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serves as a screening tool for mechanisms of early ethanol-induced steatosis. 
Furthermore, the respective mechanisms responsible for acute and chronic 
ethanol damage have been shown to be similar (see Thurman et al62 for review); 
therefore mechanistic information yielded from the acute model of ethanol 
exposure may be applicable to liver injury owing to chronic ethanol. However, 
the acute model is not without its drawbacks. Whereas there is a robust steatotic 
response associated with a single bolus dose of ethanol, there is little or no 
inflammatory or necrotic component observed with this model. To determine the 
role of PKC£ in hepatic inflammation, a chronic model of ethanol administration 
must be employed. 
One model of alcohol exposure known to cause steatohepatitis in rodents 
is the intragastric feeding model, also known as the Tsukamoto-French 
intragastric feeding model. In this model, mice receive ethanol liquid diet via a 
permanent indwelling intragastric catheter. This model features not only 
steatosis (1 week of enteral ethanol feeding) but inflammation (2 weeks) and 
necrosis (4 weeks) as wel1.63 The chronic intragastric ethanol feeding model is 
useful in that it produces all of the aforementioned pathologies (steatosis, 
inflammation, etc) and allows for the controlled delivery of high doses of ethanol 
that result in blood alcohol levels adequate to cause pathological changes. The 
controlled delivery of ethanol is important because rodents have a natural 
aversion to alcohol and as a result, ad libitum ethanol feeding models rarely 
cause elevated blood ethanol levels nor produce the severe pathological 
changes seen in the Tsukamoto-French chronic ethanol model.64 However, such 
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high doses of ethanol requiring a consistent monitoring of intoxication, requiring 
extensive animal husbandry required from this model. Furthermore, the need for 
surgical manipulation to implant the intragastric cannula, the relatively expansive 
cost of the model, coupled with the fact that little or no fibrosis is caused by this 
intragastric feeding model, signify the drawbacks of this approach. To study the 
role of PKC£ in liver fibrosis, one must employ a severe model of liver damage 
that is capable of producing a profibrotic state in mice. 
Whereas chronic ethanol exposure to rodent results in robust hepatic 
inflammation, there is only moderate fibrosis at best. Whereas there is still no 
optimal rodent model of experimental fibrosis, there are toxins that are capable of 
eliciting a fibrotic response in mice, one such chemical being CCk65 Compared 
to another common model of fibrosis (i.e. bile duct ligation), CCI4 causes a more 
fibrotic response in the liver especially compared to chronic ethanol exposure. 
However, CCb models increase transaminases to high values (-BODO lUlL) that 
are considered to be supramaximal to those found in humans with fibrosis. 
However, the CCI4 model produces pathology similar to the human disease, is 
well characterized, and has a rapid onset. Furthermore, should a therapy protect 
against fibrosis in this severe model, it is assumed that less robust fibrogeneses 
(i.e. human liver disease) will also be blunted. 
Taken together, to properly investigate the mechanisms behind the 
various stages of ALD, one must employ a variety of different models depending 
on the pathological endpoint that is being researched. The goal of this 
dissertation was to investigate the role of PKC£ in alcohol-induced hepatic 
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steatosis, steatohepatitis, and fibrosis and the proper models to investigate these 
pathologies were employed. Chapter III focuses on the role of PKCE in early 
steatosis (acute ethanol). Chapter IV investigates the role of PKCE in 
steatohepatitis (chronic intragastric feeding) and finally Chapter V demonstrates 
the ability of PKCE to contribute to hepatic fibrosis (CCI4). 
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Figure 1.1: Mechanism by which PKCE is causing hepatic insulin resistance 
DAG activates PKC£, which then increases the serine phosphorylation of 
of IRS-2, thus decreasing the tyrosine phoshosphorylation of the substrate. PI3K 
is indirectly deactivated leading to impaired glycogen production and increased 
gluconeogenesis. This figure was taken from a review by Petersen and 
Shulman.18 
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How PKCE causes insulin resistance 
Plasma fatty acid 
Petersen and Shulman. (2006) Am J Med 119: 10S-16S. 
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CHAPTER II 
MATERIALS AND METHODS 
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A. Animal Husbandry 
Mice were housed in a pathogen-free barrier facility accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care and 
procedures were approved by the local Institutional Animal Care and Use 
Committee. Six week old C57BU6J mice were obtained from Jackson 
Laboratory (Bar Harbor, ME). PKC£ knockout mice were a generous gift from the 
laboratory of Dr. Aruni Bhatnagar (University of Louisville). All knockout mice 
used in this study were generated by intercrossing 129SvJaexC57BU6 hybrid 
PKC£+I-mice as described previously.66 Food and tap water were allowed ad 
libitum prior to experimentation. 
B. Acute Model of Ethanol Exposure 
Mice were gavaged with a bolus dose of ethanol (6 g/kg) as a 20% 
solution in saline.21 Isocaloric/isovolumetric maltose-dextrin was given as a 
control. With this dosage, blood ethanol levels reached -250-300 mg/dL; 
whereas animals were ataxic, they did not lose consciousness and there were no 
deaths owing to alcohol overdose. Some mice received a PKC£ antisense 
oligonucleotide (ASO). The PKC£ ASO (sequence: 5'-
CTCGCAGATTTTGATCTT AA-3') was a kind gift from Dr. Brett Monia (Isis 
Pharmaceuticals Inc). The method of injection for the ASO was similar to the 
protocol described in Samuel et al67 but with slight modifications to account for 
the use of mice. Specifically, mice received the PKC£ ASO or vehicle saline at a 
dose of 25 mg/kg (Lp.) twice a week for four weeks. Mice were sacrificed 0-12 
hours after ethanol gavage. Animals were anesthetized with ketamine/xylazine 
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(100/15 mg/kg, i.m.) and blood collected from the vena cava just prior to 
sacrifice. Citrated plasma was stored at -80DC until further analysis. Portions of 
liver tissue were frozen immediately in liquid nitrogen, while others were frozen-
fixed in OCT mounting media (Tissue Tek, Hatfield, PA) for subsequent 
sectioning and mounting on microscope slides. 
C. Immunoblotting for PKCE 
Western Blotting for PKCE was performed by Dr. Jun Zhang as described 
previously.68 Specifically, total hepatic protein was isolated from snap-frozen 
liver samples using isolation buffer [50 mM Tris-HCI (pH 7.5),10 mM EGTA, and 
50 mM B-mercaptoethanol] containing protease inhibitors (Roche, Penzberg, 
Germany). The homogenates were centrifuged at 100xG to remove the 
unbroken cells. The supernatant was then centrifuged at 1 OO,OOOxG for 1 h at 
4°C. The resulting supernatant represented the cytosolic fraction. To solubilize 
the pellet, the pellet was resuspended into the isolation buffer with 0.1 % NP-40, 
and incubated 30 min on ice followed by brief sonication. All buffers used for 
protein extraction contained protease, tyrosine phosphatase, and 
serine/threonine phosphatase inhibitor cocktails (Sigma, St. louis, MO). 
Respective Iysates (100 I1g protein/well) were separated on 10% SDS-
polyacrylamide gel. Proteins were then transferred to polyvinylidene difluoride 
membranes using a semidry electroblotter (Amersham, Piscataway, NJ). The 
resulting blots were probed with antibodies against PKCE (BD Transduction 
laboratories, San Jose, CA) and bands visualized with the ECl plus kit 
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(Amersham Biosciences, Piscataway, NJ). To ensure equal loading, all blots 
were stained with Ponceau red. 
D. Lipid Determinations 
Mouse livers were homogenized in 2x phosphate buffered saline. Tissue 
lipids were extracted with methanol:chloroform (1 :2), dried in an evaporating 
centrifuge, and resuspended in 5% fat-free bovine serum albumin. Colorimetric 
assessments of hepatic triglycerides or non-esterified fatty acids (NEFA) were 
carried out using standard kits (Thermotrace, Melbourne, Australia and Roche, 
Penzberg, Germany). Values were normalized to protein in homogenate prior to 
extraction as determined by the Bradford assay (Bio-Rad Laboratories, Hercules, 
CA). 
E. Quantification of DAG with electrospsray ionizationl mass spectrometry 
For the determination of hepatic DAG levels, hepatic lipids were extracted 
by an aqueous solution of chloroform and methanol as described by Bligh and 
Dyer 69. Quantification of DAG was performed as described in Callender et al 70. 
Specifically, DAG was separated from phospholipids by silica gel column 
chromatography with 65:35:0.7 CHCI3:CH30H:H20 as the elution buffer. Before 
use, each column was plugged with glass wool and packed with 6 cm of silica gel 
and equilibrated with 10 ml of the eluent. To recover DAG, the first 2 ml of eluent 
were collected and dried in a vacuum and then resuspended in 120 ~I of 9: 1 
CH30H:CHCI3 with 5 ~I of 100 mM CH3COONa. To evaluate the recovery of 
DAG during separation, all liver extracts were spiked with 100 pmoles of a known 
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DAG standard (DAG 28:0). Samples were then analyzed by J. David Hoetker via 
electrospray ionization mass spectrometry on a Micromass ZMD equipped with a 
Harvard Apparatus syringe pump at an infusion rate of 10 !-II/min in a positive 
ionization mode at a range of m/z 20 to 2,000. Na+ adducts were used for the 
detection of individual DAG species. Select peaks were quantified by comparing 
to previously determined standards and then identified by fragmentation via 
ESI/MS/MS. 
F. RNA Isolation and Real-Time RT-peR 
Message levels of select genes were detected by real-time reverse-
transcriptase PCR, which is routine by this group.14, 71 Total RNA was isolated 
from liver tissue using RNA STAT 60 (Tel-Test, Friendswood, TX). Polymerase 
Chain Reaction primers and fluorogenic probes were designed using Primer 
Express (Version 1.5, Applied Biosystems, Foster City, CA). Primers were 
designed to cross introns, to ensure only cDNA and not genomic DNA is 
amplified (see Table I). The fluorogenic MGB probe was labeled with the 
reporter dye FAM (6-carboxyfluorescein). TaqMan Universal PCR Master Mix 
(Applied Biosystems) was used to prepare the PCR mix. The 2X mixture is 
optimized for TaqMan reactions and contains AmpliTaq gold DNA polymerase, 
AmpErase, dNTPs with UTP and a passive reference. Primers and probe were 
added to a final concentration of 300nM and 100nM respectively. cDNA was 
made from 1 Jlg of total RNA using the Advantage for RT for PCR kit (BD 
Biosciences, Palo Alto, CA) following manufacture's instruction. The 
amplification reactions were carried out in the ABI Prism 7700 sequence 
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detection system (Applied Biosystems) with initial hold steps (50°C for 2 min, 
followed by 95°C for 10 min) and 40-50 cycles of a two-step PCR (92°C for 15 
sec, 60°C for 1 min). The fluorescence intensity of each sample was measured 
at each temperature change to monitor amplification of the target gene cDNA. 
The fluorescence signal increased when the probe binds to the single stranded 
template DNA and is digested by the 5'-3'-exonuclease activity of the AmpliTaq 
Gold DNA polymerase. Digestion of the probe releases the fluorescent reporter 
dye (FAM) from the quencher. The comparative CT method was determined 
used to fold differences between samples. The comparative CT method 
determines the amount of target, normalized to an endogenous reference (~­
actin) and relative to a calibrator (2-M Ct). The purity of PCR products were 
verified by gel electrophoresis. 
G. Glucose-6-Phosphatase Activity 
The enzymatic activity of glucose-6-phosphatase was measured by the 
production of phosphate from glucose-6-phosphate as described by Kaidanovich-
Beilin et af2 with minor modifications. Using a hand-held homogenizer, livers 
(-100 mg) were homogenized in 500 IJI of 250 mM sucrose-HEPES buffer (pH 
7.4). Homogenates were centrifuged for 10 min at 3000xG (4°C). To 100 IJI of 
this supernatant, 25 IJI of taurocholic acid was added and incubated on ice for 30 
min. After incubation, 175 IJI of homogenization buffer was mixed with this 
solution. A 60 IJI aliquot was then mixed with 140 IJI of reaction buffer (25 IJI of 
0.5 M Tris HCI buffer, pH 6.5, 20 IJI of 100 mg/ml bovine serum albumin, 40 IJI of 
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100 mM glucose-6-phosphate, and 50 III of distilled water). This solution was 
then incubated at 3JDC for 0 and 20 min. 140 III of stop solution (15% ice cold 
trichloroacetic acid) was added to both solutions (0 and 20 min). The samples 
were the centrifuged at 3000xG for 10 min at 4°C. To 140 III of supernatant, 
phosphate reagent (5% ammonium molybdate tetrahydrate in 4 N HCI and 1 % 
Iron (II) sulfate heptahydrate) was added. This solution was incubated at 3JDC 
for 10 min. The shift in absorbance caused by the reaction of phosphate and 
ammonium molybdate tetrahydrate was read for each sample at 650 nm and 
results normalized to protein content. 
H. Glucokinase Activity 
The activity of glucokinase was measured by monitoring the absorbance 
of NADH formed from glucose-6-phosphate dehydrogenase as described by 
Rossetti et al.73 Briefly, livers (-100mg) were homogenized in 1 ml of HEPES 
buffer (50 mM, pH 7.4) containing 100 mM KCI, 1 mM EDTA, 5 mM MgCI2 , and 
2.5 mM dithioerythritol. The homogenates were then centrifuged at 100,000xG 
for 45 min at 4°C. 501-11 of supernatant was then mixed with an ATP reagent 
buffer (100 mM KCI, 7.5 mM MgCb, 2.5 mM dithioerythritol, 10 mg/ml bovine 
serum albumin, 100 mM glucose, .5 mM NAD+, 4 units/ml of glucose-6-
phosphate dehydrogenase in 50 mM buffer, pH 7.4). The absorbance of NADH 
was read at 340 nm at 37°C for 20 min and results normalized to protein. 
I. Tsukamoto-French Model of Chronic Alcohol Administration 
All necessary surgeries for this model were completed by Dr. Luping Guo, 
a senior research associate. Surgical implantation of the intragastric cannula 
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and enteral feeding was performed as described previously.14 Specifically, 
C57BU6J mice were anesthetized with isoflourane and a gastric cannula was 
implanted into the forestomach. Cannulas were fixed to the abdominal wall and 
secured with an anchoring button. Ampicillin and gentamicin (antibiotics) were 
administered via the intraperitoneal cavity. Briefly, a liquid diet described by 
Thompson and Reitz74 supplemented with lipotropes as detailed in Morimoto et 
aes was prepared daily. Either ethanol-containing or isocaloric maltose-dextrin 
(control) diet was fed for 4 weeks as described elsewhere. The initial rate of 
ethanol delivery (16 g/kg/day) was increased in a step-wise manner 1 g/kg/ every 
2 days until the end of the first week and then 1 g/kg/4 days until the end of the 
experiment. 
J. Histology 
Liver pathology was scored as described by Nanji et ae6 : steatosis < 
25%, 1; 25-50%, 2; 50-75%, 3; > 75%, 4; 1 or 2 for 1 or more inflammatory, 
necrotic, or fibrotic foci. Neutrophil accumulation in the livers was assessed by 
staining tissue sections for chloracetate esterase, a specific marker for 
neutrophils, using the napthol AS-D chloracetate esterase kit (Sigma, St. Louis 
MO).71,77 Extracellular matrix accumulation in liver sections was determined by 
staining with Sirius red-fast green.78 
Sirius red staining was quantified by image analysis. Specifically, a 
Universal Imaging Corp. Image-1/AT image acquisition and analysis system 
(Chester, PA) incorporating an Axioskop 50 microscope (Carl Zeiss, Inc., 
Thornwood, NY) was used to capture and analyze 5 non-overlapping fields per 
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section at 100x final magnification. Image analysis was performed using 
modifications of techniques described previously.79 Detection thresholds were 
set for the red color based on an intensely labeled point and a default color 
threshold. The degree of labeling in each section was determined from the area 
within the color range divided by the total area. 
K. Determination of individual free fatty acid species by gas 
chromatography 
Biological samples were processed as described by Lepage and Roy.ao 
Briefly, 30 mg of liver homogenate was weighed in glass tubes. While stirring, 
200 III of acetyl chloride was slowly added. Tridecanoic acid (13:0) was used as 
internal standard. The tubes were tightly closed with Teflon-lined caps and 
subjected to methanolysis at 1 OO°C for 1 hr. After adding 5 ml of 6% K2C03, the 
fatty acid esters were extracted twice with hexane and an aliquot of the hexane 
upper phase was injected into the chromatograph. FFA were chromatographed 
as methyl esters on an Agilent 6890 N GC equipped with an HP-5 capillary 
column (50 m x 0.2 mm i.d. x 0.5 IJm phase thickness) coupled to a 5973 
detector for mass spectrometry analysis. Helium was used as carrier gas. The 
split ratio was 20:1. The injection port temperature was 280°C and the detector 
was 250°C. The GC column temperature was set at 150°C for 3 min, increased 
by 5°C/min until 260°C and then by 20°C/min until 300°C and kept at this 
temperature for 4 min. 
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L. Clinical Chemistry 
Serum indices of hepatic injury (AST, AL T) were measured using kits 
(Sigma) and spectrophotometric techniques routine in this laboratory.81 Urine 
alcohol was measured using standard spectrophotometric techniques82 also 
routine in this laboratory 81 
M. Chronic Model of CCI4 Exposure 
Mice were exposed with CCI4 as described previously.83 Mice were 
administered CCI4 (1 ml/kg i.p.; diluted 1:4 in olive oil; Sigma-Aldrich, St. Louis, 
MO) 2x/wk for 4 wk. Twenty-four h after the last CCI4 administration, mice were 
anesthetized by injection of a ketamine HCUxylazine solution (100/15 mg/kg i.m.; 
Sigma-Aldrich, St. Louis, MO). 
N. Zymography 
To determine the hepatic activity of MMPs, total hepatic protein was 
extracted using a lysis buffer consisting of 10 mM cacodylic acid (pH 5.0) 
containing 150 mM NaCI, 1 f.lM ZnCI, 15 mM CaCb, 1.5 mM NaN3, and 0.01 % 
Triton X-100. Lysates were then diluted in 2x sample buffer and separated on 
10% SOS-polyacrylamide gels containing 0.1 % gelatin. Gels were incubated 
twice for 30 min in 2.5% v/v Triton-X-1 00 solution and washed three times 30 min 
in developing solution (50 mM Tris, 0.1 M glycine, 0.1 M NaCI, ph 8.0) followed 
by a 40 h incubation in developing buffer at 37°C. The caseinolytic activity was 
detected by staining the gel (0.1 % amido black, 45% methanol, 10% acetic acid) 
for 2 h and then destaining (45% methanol, 10% acetic acid) for 30 min. 
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Densitometric analysis was performed using Image Quant software (Amersham 
Biosciences Corp, Piscataway, NJ). 
O. Immunofluorescent Detection of Fibrin Accumulation 
For immunofluorescent detection of fibrin deposition, sections of frozen 
liver (6-llm thick) were fixed in 10% buffered formalin containing 2% acetic acid 
for 30 min at room temperature; this acid step solubilizes all but cross-linked 
fibrin. Sections were blocked with PBS containing 10% horse serum (Pierce, 
Rockford, IL) for 30 min, followed by incubation overnight at 4°C with affinity 
purified rabbit anti-human fibrinogen IgG (Dako North America, Inc., Carpinteria, 
CA) diluted in blocking solution. Sections were washed three times for 5 min 
each with PBS and incubated for 3 h with donkey anti-rabbit antibody conjugated 
to Alexa 488 (Invitrogen, Carlsbad, CA). Sections were washed with PBS and 
visualized using a confocal microscope (Zeiss Axiovert 100 LSM 510; Carl Zeiss 
Inc., Thornwood, NY) and LSM 510 software. No staining was observed in 
controls for which the primary or secondary antibody was excluded from the 




PKCE PLAYS A CAUSAL ROLE IN ACUTE ETHANOL-INDUCED STEATOSIS 
The text of this chapter was published in Archives of Biochemistry and 
Biophysics, 482(1-2), 104-1 (2009). 
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A. Introduction 
Alcoholic liver disease is one of the leading causes of death in the world,1 
affecting millions of people per year. From 1985 to 1992, it is estimated that over 
$148 billion was spent to treat people with ALD in the US alone.3 However, due 
to poor understanding of the mechanisms underlying ALD, there is still no FDA-
approved therapy to prevent or reverse the progression of this devastating 
disease. The molecular mechanisms responsible for ALD must be delineated in 
order to identify an effective therapy to halt or reverse the pathological changes 
associated with ALD. 
The first histological change associated with ALD is hepatic steatosis. 
Whereas steatosis was once thought to be an inert pathology of ALD, more 
recent evidence has indicated that blunting or blocking steatosis could help 
prevent the progression of ALD.9, 28, 84 It has long been established that the 
metabolism of alcohol directly contributes to hepatic steatosis caused by this 
drug.8s Specifically, the metabolism of alcohol increases the ratio of 
NADH:NAD+, which subsequently inhibits l3-oxidation of fatty acids by 
hepatocytes. Alcohol metabolism also increases the rate of esterification of fatty 
acids.12 These changes in fatty acid flux caused by ethanol metabolism 
subsequently cause hepatic triglycerides to accumulate. However, previous 
studies suggest that other factors may contribute to steatosis caused by ethanol. 
Specifically, many pharmacologic agents and genetic alterations (e.g. knockout 
mice) have been shown to block hepatic steatosis in rodent models of alcohol 
exposure; for example, mice deficient in prooxidant-producing enzymes (e.g., 
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NADPH oxidase and iNOS)13. 14 or LPS binding/signaling molecules (e.g., CD14, 
TLR4, and LBP), all have less steatosis in response to alcohol compared to wild-
types. 15-17 However, these pharmacologic/genetic changes, which protected 
against steatosis in previous studies, had no apparent effect on alcohol 
metabolism. It is therefore likely alcohol metabolism is not the sole causal factor 
in ethanol-induced steatosis. 
One alternate mechanism by which ethanol may cause steatosis is via 
inducing hepatic insulin resistance. It has been reported that both chronic and 
acute ethanol exposure cause hepatic insulin resistance in animal models.19 The 
effect of impaired insulin signaling on hepatic lipid accumulation is well-
documented, especially in non-alcoholic fatty liver disease (NAFLD; see 18 for 
review). Whereas less well-characterized, it is likely that insulin resistance has a 
similar effect on lipid metabolism in alcohol-induced liver disease. Furthermore, 
insulin resistance is a known risk factor for the development of ALD in humans.2o 
Recent work from this group has shown that the insulin-sensitizing drug, 
metformin, blocks fatty liver caused by ethanol exposure, supporting a link 
between insulin resistance and hepatic steatosis after ethanol exposure.21 
A possible mechanism by which ethanol is causing hepatic insulin 
resistance and the subsequent steatosis is via activating Protein Kinase C 
epsilon (PKC£).18 It is proposed that PKC£ inhibits the tyrosine phosphorylation 
of insulin receptor substrate-2 (IRS-2) and thereby impairs hepatic insulin 
signaling.18 It was recently shown that the activation of PKC£ plays a causal role 
in hepatic insulin resistance in experimental NAFLD.86 Here, using an acute 
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mouse model, the hypothesis that ethanol exposure activates PKCE and that 
PKCE contributes to hepatic steatosis was directly tested. 
B. Materials and Methods 
1. Animals and Treatments 
Mice were treated with ethanol as described in Chapter II. Additionally, 
some mice were treated with a PKCE ASO to decrease the expression of PKCE 
to 20% of control mice. 
2. Immunoblots 
Immunoblotting to compare the membrane and cytosolic fractions of PKCE 
was performed as described in Chapter II. 
3. Lipid Determinations 
Frozen sections of liver were stained for hepatic lipids via oil red 0 
staining. Determination of hepatics lipids (Le. NEFA, triglycerides, and DAG) 
was performed as detailed in Chapter II. 
4. RNA isolation and real-time RT-peR 
See detailed method in Chapter II. 
5. G6Pase Activity 
The activity of G6Pase was measured by a colorimetric assay as 
described in Chapter II. 
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6. G K Activity 
GK activity was determined spectrophotometrically as detailed in Chapter 
II. 
C. Results 
1. Ethanol increases hepatic lipids 
Figure 1 shows the effect of acute ethanol on hepatic triglycerides and 
non-esterified fatty acids (NEFA) in wild-type mice. The hepatic triglyceride 
content in isocaloric maltose-dextrin mice was similar to those for na'ive animals. 
As has been observed previously (e.g.,21), ethanol caused a progressive 
increase in triglycerides during the course of the study; at the 12 h timepoint, 
values were -20-fold higher than maltose-dextrin controls (Figure 1, open 
squares). Acute ethanol also increased hepatic NEFA content, but the temporal 
pattern differed from the response of hepatic triglycerides. Specifically, hepatic 
NEFA were significantly increased by ethanol -5 -fold 1 h after exposure, and 
then progressively returned to basal levels by the 12 h timepoint (Figure 1, 
closed circles). 
2. Effect of ethanol on hepatic DAG levels and PKCE activation 
As mentioned previously, DAG are major mediators of PKCe: activation.14 
Since de novo DAG synthesis requires NEFA, it was hypothesized that the 
increase in NEFA caused by alcohol may also increase DAG levels in the liver. 
Therefore, the effect of acute ethanol on hepatic DAG was determined (Figure 
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3.2 and .33). Figure 3.2 shows representative chromatograms from control- and 
ethanol-treated mice, while Figure 3.3 shows summary data. Whereas long 
chained DAG were in general increased 2 h after ethanol exposure (Figure 3.2 
and 3.3, upper panel, not all species responded equally. The effect of ethanol on 
four specific DAG species was determined in Figure 3.3. DAG 32: 1 (m/z 589), 
DAG 34:2 (m/z 615) and DAG 38:6 (m/z 663) were all significantly increased 
(-1 .5-fold) due to acute ethanol. DAG 32:0 (m/z 577) with an ether linkage at the 
Sn1 position showed an even more robust effect of ethanol with values -3-fold 
higher than controls (Figure 3.3). Interestingly, only long chained DAG were 
affected, whereas short and medium chained DAG were not increased by 
ethanol. 
Figure 3.4 shows the effect of ethanol on the ratio of membrane to 
cytosolic PKC£. An increase in this ratio is an index of increased activation of 
this enzyme. Maltose dextrin administration had no significant effect on the 
translocation of PKC£ to the membrane compared with naIve mice. At 1 h after 
ethanol exposure, there was a significant increase (-50%) in PKC£ membrane 
localization. This effect diminished initially to basal levels, but then returned at 8 
h and progressively increased with values -3-fold higher than controls 12 h after 
ethanol exposure (Figure 3.4). 
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3. Effect of ethanol on plasma insulin and glucose and expression of 
insulin-responsive genes 
As mentioned in the Introduction of this chapter, it is known that acute and 
chronic ethanol causes hepatic insulin resistance in rodents. For example, 
Onishi et al. 19 showed that bolus ethanol caused insulin resistance within 2 h 
after administration, as determined by both hyperinsulinemic-euglycemic clamp, 
as well as by the phosphorylation status of IR and IRS-1 and -2. To corroborate 
these previous findings under the current conditions, the effect of ethanol on 
surrogate markers of insulin resistance and signaling were determined. 
Accordingly, the effect of ethanol on plasma insulin and glucose was determined 
(Figure 3.5, upper panel). 2 h after ethanol exposure, there was a significant 
increase (-3-fold) in plasma insulin levels (Figure 3.5, upper panel, closed 
circles), which then progressively decreased to basal levels -12 h after ethanol 
exposure. Despite this increase in plasma insulin, the concentration of plasma 
glucose did not significantly decrease. Indeed, ethanol caused a significant 
increase (-50%) in plasma glucose concentrations, 4 h after ethanol exposure 
(Figure 3.5, upper panel, open squares). 
In addition to determining plasma concentrations of insulin and glucose, 
the effect of ethanol on the expression and activity of inSUlin-responsive genes 
was also determined. Specifically, the effect of ethanol on mRNA and protein 
activity of 2 key genes regulated by insulin was determined (Figure 3.5). 
Messenger RNA levels of G6Pase, which is downregulated by insulin, was 
significantly upregulated by ethanol (Figure 3.5, middle panel, closed circles) with 
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a maximal value (-8-fold) 2 h after exposure. After the 2 h timepoint, expression 
progressively returned to basal with values 12 h after exposure not significantly 
different than controls. Bolus ethanol also caused a significant increase in 
hepatic G6Pase protein activity (Figure 3.5, middle panel, open squares), but the 
effect of ethanol on enzyme activity was not as robust as observed with mRNA 
expression. Messenger RNA levels of GK, a gene which is upregulated by 
insulin, was significantly decreased -5-fold by ethanol (Figure 3.5, lower panel, 
closed circles) and this effect was maintained throughout the course of the study. 
GK enzyme activity was also significantly decreased by ethanol (Figure 3.5, 
lower panel, open squares), but this effect on protein activity was again less 
robust than observed with mRNA expression, and had recovered by -4 h after 
ethanol exposure. 
4. PKCE knockdown or knockout blunts ethanol-induced steatosis 
As mentioned in the Introduction, PKC£ contributes to steatosis in models 
of NAFLD.86 Since PKC£ was activated by ethanol in the current work (Figure 
3.4), the effect of 'knocking-down' PKC£ with ASOs or genetic ablation of the 
PKC£ gene ('knockout') on ethanol-induced steatosis was determined by oil red 
o staining and by quantitation of hepatic triglycerides (Figure 3.6). Steady state 
levels of PKC£ mRNA in ASO-exposed mice were significantly decreased to 23.3 
± 4.7% of levels found in ethanol-exposed mice (data not shown). Lipid staining 
from mice receiving maltose dextrin was minimal and similar to na"ive chow-fed 
animals (Figure 3.6, upper left panel). Analogous to previous studies in this 
model,21 ethanol increased oil red 0 staining in the liver (Figure 3.6, upper right 
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panel) with both macro- and micro-vesicular steatosis obseNable at the 12 h 
timepoint. This effect of ethanol on lipid accumulation was blunted in livers from 
PKC£ ASO-treated mice; this protective effect in the ASO mice appeared to 
affect macrovesicular steatosis (large lipid droplets) more robustly than the 
microvesicular droplets (Figure 3.6, lower left panel). ASO administration also 
blunted the increase in triglycerides caused by ethanol by -50%; a similar 
protective effect was obseNed in PKC£ knockout mice (Figure 3.6, lower right). 
5. The effect of a PKCE ASO on ethanol-induced changes on insulin-
responsive genes 
As mentioned in the Introduction, PKC£ activation and insulin resistance 
have been linked in experimental NAFLD.86 The effect of a knocking down PKC£ 
on the ethanol-induced alterations in insulin-responsive genes (see Figure 3.5) 
caused by alcohol was therefore determined under these conditions (Figure 3.7). 
Pretreatment with the PKC£ ASO significantly (-2-fold) blunted the upregulation 
of G6Pase owing to ethanol (Figure 3.7, upper panel); however the 
downregulation of GK caused by ethanol was not significantly affected in PKC£ 
ASO-treated mice (Figure 3.7, lower panel). 
D. Discussion 
Steatosis is a critical stage in the pathology of ALD, as it has been shown 
that the degree of steatosis can be predictive of future stages of ALD.84 Also, the 
prevention of steatosis could actually protect against more severe stages of ALD 
such as fibrosis and cirrhosis. 9 Thus, studying the causes of lipid accumulation 
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in this acute model is useful not only for screening new mechanisms of alcohol-
induced steatosis, but it may also identify therapies to treat ALD. It was 
previously shown that PKC£ plays a causal role in hepatic steatosis in 
experimental NAFLD.86 However, the role of PKC£ in ethanol-induced steatosis 
has not been determined and was subsequently the focus of this study. Here, 
using an acute model of ethanol exposure,21 results were provided that support a 
causal relationship between PKC£ activation and ethanol-induced steatosis. 
First, it was demonstrated that ethanol increases the activation of PKC£, 
concomitant with indices of insulin resistance. Next, it was determined that the 
inhibition of PKC£ protects against insulin resistance as well as steatosis both 
owing to acute ethanol. 
How does PKCE cause fatty liver? 
One possible mechanism by which PKC£ causes fatty liver is by impairing 
hepatic insulin signaling.18 In previous studies, it has been shown that both acute 
and chronic exposure to ethanol, causes hepatic insulin resistance in rodents 
(e.g.,19). To verify this effect of ethanol under these conditions, plasma levels of 
insulin and glucose, as well as the expression of insulin responsive genes (GK 
and G6Pase) were investigated. An index of insulin resistance is 
hyperinsulinemia as a consequence of the body no longer responding to the 
normal levels of insulin. Acute ethanol significantly increased (-3-fold) plasma 
concentrations of insulin (Figure 3.5, upper panel, closed circles), but had no 
effect on plasma glucose; this apparent inability of insulin to decrease plasma 
glucose under these conditions is in line with previous studies using euglycemic 
41 
clamps.19 Ethanol also changed the expression profiles of the insulin responsive 
genes in a manner that is suggestive of insulin resistance (Figure 3.5, 
middle/lower panel). Specifically during times of unimpaired insulin signaling, GK 
expression is upregulated by insulin while G6Pase expression is downregulated. 
This effect of insulin contributes to the shift in the metabolism of the cell from 
glucose production to glucose utilization. However, Figure 3.5 illustrates that 
acute ethanol increases G6Pase expression while decreasing GK, which is a 
pattern opposite to that caused by insulin. Taken together, these data support 
the hypothesis that ethanol causes hepatic insulin resistance in vivo under the 
current conditions. 
The effect of ethanol on insulin responsive genes was also determined in 
mice that received the PKCE ASO (Figure 3.7). Interestingly, whereas the 
upregulation of G6Pase caused by ethanol was almost completely blunted by the 
ASO, the downregulation in GK was not affected by the ASO. These data 
indicate that PKCE mediates some aspects of insulin resistance, but not others. 
This may not be surprising, given the fact that these two genes are regulated by 
insulin via different downstream signaling cascades.s7, ss Therefore, PKCE could 
inhibit the cascade that down regulates G6Pase by insulin, but not be involved in 
the cascade that upregulates GK by insulin. These results suggest that PKCE 
may be a causal player in part, for the impaired hepatic insulin signaling caused 
by this model of acute ethanol exposure. 
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Potential mechanism by which ethanol activates PKCE 
One of the well-known metabolic effects of ethanol metabolism is an 
increase in the NADH:NAD+ ratio; as mentioned in the Introduction of this 
chapter, this increased pyridine nucleotide redox ratio inhibits the ~-oxidation of 
free fatty acids, which then causes NEFA to accumulate.8s The rapid and robust 
increase in hepatic NEFA observed here (Figure 3.1) are likely attributable to this 
mechanism. DAG can be produced by a number of different mechanisms, 
including de novo synthesis via the triacylglycerol pathway. In addition to 
increasing NEFA supply for DAG synthesis, the metabolic effect of ethanol 
metabolism is likely to increase other metabolites that are required DAG 
synthesis (e.g., dihydroxyacetone phosphate, a-glycerophosphate, etc.).89 For 
example, glyceraldehyde phosphate dehydrogenase is inhibited and glycerol-3-
phosphate dehydrogenase is activated by an increase in the NADH:NAD+ ratio 
90; such an effect will be expected to cause dihydroxyacetone phosphate and a-
glycerophosphate to accumulate, which would further favor DAG formation from 
NEFA. 
The blockade of expression of PKC£ was only able to confer partial 
protection against fatty liver owing to acute ethanol exposure. This result 
suggests that other mechanisms independent of PKC£ are also playing a role in 
steatosis caused by ethanol. For example, there are many isoforms of PKC 
besides E that have been shown to cause insulin resistance.s8 Therefore, it is 
possible that one or more of these PKC isoforms could be collaborating with 
PKC£ to cause ethanol-induced steatosis. Alternatively, agents that cause 
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insulin resistance through mechanisms unrelated to the PKC family could also be 
contributing to fatty liver owing to ethanol. Finally, it may very well be possible 
that the redox inhibition of the ~-oxidation of free fatty acids caused by the 
metabolism of alcohol is responsible for the remaining steatosis that is not 
blunted by the PKC£ ASO. Clearly, all of these possible mechanisms could be 
working in tandem with PKC£ to cause ethanol-induced fatty liver. 
Summary and Conclusions 
The main goal of this work was to identify and characterize the role of 
PKC£ in early alcohol-induced liver disease. The experiments described here 
suggest a potential mechanism by which PKC£ is activated as well as the means 
by which PKC£ contributes to ethanol-induced steatosis. Specifically, ethanol 
accumulates NEFA which then increases DAG synthesis. DAG allosterically 
activates PKC£, which then impairs insulin signaling and causes hepatic 
steatosis. Taken together, the results of this study support the hypothesis that 
PKC£ plays a causal role in ethanol-induced steatosis. PKC£ may therefore 
present a therapeutic target that could prevent and/or halt the progression of 
ALD. 
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Figure 3.1: Effect of acute ethanol on hepatic triglycerides and NEFA. 
Quantitation of triglycerides (open squares) and NEFA (closed circles) 
was determined via colormetric assays. Data represent means±SEM (n=4-6) 
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Figure 3.2: Effect of acute ethanol on hepatic DAG levels. 
Positive electron spray ionization mass spectrums are shown from liver 
extracts after chromatographic separation on a silica gel column to remove polar 
phospholipids. 1.48 I-Ig phosphate of sample was loaded per column. Since Na+ 
adducts were used to detect DAG species, the m/z value represents the 
molecular weight of the respective DAG plus the weight of a sodium molecule 
(M+Na +). Representative chromatograms of livers from control and ethanol-
exposed mice are shown with peaks identified by fragmentation to be a known 
DAG: DAG 32:1 with an ether linkage (M+Na+=575), DAG 32:0 with an ether 
linkage (M+Na+=577), DAG 32:1 (M+Na+=589), DAG 34:2 (M+Na+=615), DAG 
34:1 (M+Na+=617), DAG 36:4 (M+Na+=639) and DAG 38:6 (M+Na+=663). The 
series numbers indicate the total number of carbons in the acyl chains on the 
DAG molecule. The peak at m/z 535 corresponds to the internal standard (DAG 
28:0). 
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Figure 3.3: Effect of acute ethanol on specific DAG species. 
Quantification of DAG was performed as described in Chapter II. 
Summary data of mean results of control (red) and ethanol-exposed (green) mice 
are shown in the upper panel (see also Figure 3.2). The lower panel compares 
and summarizes the relative amounts of select DAG identified in the upper panel. 
Data represent means±SEM (n=4-6) and are normalized to J.Jg phosphate. a, 
p<O.05 compared to the absence of ethanol. 
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Figure 3.4: Effect of acute ethanol on the activation of PKCE in mouse liver. 
Western blot of PKCE was performed as described in Chapter II. 
Representative blots are shown depicting the membrane and cytosolic fractions 
of PKCE. The data represent means±SEM (n=4-6). a, p<O.05 compared to the 
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Figure 3.5: Effect of acute ethanol on the plasma concentrations of insulin 
and glucose and on the expression/activity of insulin-responsive genes in 
mouse liver. 
Plasma concentrations of insulin (upper panel, closed circles) and glucose 
(upper panel, open squares) were determined by ELISA. Real-time rtPCR for 
G6Pase (upper panel, closed circles) and GK (lower panel, closed circles) was 
performed as described in Chapter II, and results were normalized to ~-actin. 
G6Pase (upper panel, open squares) and GK (lower panel, open squares) 
protein activity was determined spectrophotometrically as described in Materials 
and Methods. Data are means±SEM (n=4-6) and real-time rtPCR data are 
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Figure 3.6: Effect of PKCE ASO on ethanol-induced steatosis. 
Oil red 0 staining was performed as described in Chapter II. 
Representative photomicrographs (200xmagnification) of saline-treated wild-type 
mice receiving maltose-dextrin (upper right panel) and ethanol (upper left panel), 
as well as PKCE ASO treated-mice receiving ethanol (lower left panel) are shown. 
Quantitation of triglycerides (lower right panel) was performed via a colorimetric 
assay as described in Chapter II. Data represent means±SEM (n=4-6) and are 
normalized to mg protein. a, p<O.05 compared to the absence of ethanol; b, 
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Figure 3.7: The effect of the PKCE ASO on ethanol-induced changes on the 
expression of insulin-responsive genes 1 hour after ethanol exposure in 
mouse liver. 
Real-time rtPCR for G6Pase (upper panel) and GK (lower panel) was 
performed as described in Chapter II, and results were normalized to ~-actin. 
Data are means±SEM (n=4-6) and are reported as fold of control values. a, 
p<O.05 compared to the absence of ethanol as determined; b, p<O.05 compared 
with saline-treated exposed to ethanol. 
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PKCE contributes to chronic ethanol-induced steatosis in mice but not 
inflammation and necrosis 
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A. Introduction 
Alcoholic liver disease is a serious concern for the world's population, 
causing millions of deaths per year.1 The pathological steps of ALD are well 
understood: steatosis first develops, followed by inflammation and necrosis; if the 
insult(s} persists, fibrosis and cirrhosis can then develop. Whereas the disease 
progression is well understood, our knowledge of the mechanisms involved in 
causing the disease is lacking; as a result, there is no FDA-approved therapy to 
treat or reverse ALD. Steatosis is a critical stage in the pathology of alcoholic 
liver disease (ALD). Although steatosis was once thought to be an inert 
pathology of ALD, more recent evidence has indicated that blunting or blocking 
steatosis could help prevent the progression of ALD.9, 28, 84 Therefore, 
pharmacologically targeting the cause(s} of ethanol-induced steatosis is a 
promising potential therapy for ALD. 
Recent evidence has suggested that protein kinases c, in particular 
protein kinase c-epsilon (PKCE), can contribute to steatosis in experimental non-
alcoholic fatty liver disease (NAFLD}.86 Specifically, PKCE impairs the tyrosine 
phosphorylation of the insulin receptor substrate-2 (IRS-2), which leads to 
hepatic insulin resistance, impaired lipid metabolism, and subsequent steatosis.86 
Chapter III in this dissertation showed that PKCE also plays a causal role in acute 
ethanol-induced steatosis in mice.91 Results from that study support the working 
hypothesis that the inhibition of rl-oxidation of fatty acids caused by ethanol 
metabolism increases the fatty acid supply for de novo diacylglycerol (DAG) 
synthesis. This increase in DAG allosterically activates PKCE, which then 
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contributes to the increase in hepatic triglycerides caused by ethanol by inducing 
insulin resistance (Chapter 111).91 Thus, PKCE activation may be a shared 
mechanism of hepatic steatosis in ALD and NAFLD. 
Whereas acute bolus ethanol induces a robust steatotic response in the 
liver (Chapter 111),91 there is little or no inflammation or necrosis caused by this 
dose regimen of ethanol in rodents. PKCE has been shown to contribute to 
inflammation in response to various insults (e.g. LPS), which suggests that PKCE 
may also contribute to more advanced stages of ALD (e.g. steatohepatitis).92 
Furthermore, as mentioned above, blunting steatosis caused by alcohol may in 
and of itself prevent later phases of ALD. This potential role of PKCE in these 
later stages of experimental ALD has not yet been directly studied. Therefore, 
the purpose of this study was to determine the role of PKCE in chronic ethanol-
induced liver damage. Specifically, the effect of knocking down PKCE on liver 
damage caused by chronic enteral alcohol exposure was determined in mice. 
B. Materials and Methods 
1. Animals and Treatments 
Mice were exposed to ethanol via the Tsukamoto-French model described 
in Chapter II. Some animals received a PKCE ASO as mentioned in Chapter III. 
2. Histological analysis 
See detailed method in Chapter II. 
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3. Clinical Chemistry 
See detailed method in Chapter II. 
4. RNA isolation and Real-Time PCR 
See detailed method in Chapter II. 
5. Quantitation of individual free fatty acid species 
Specific free fatty acid species were quantitated by gas chromatography 
as described in Chapter II. 
6. Immunoblotting 
Western blotting of PKCE was performed as described in Chapter II. 
7. Lipid Determinations 
See detailed method in Chapter II. 
C. Results 
1. Body weight and urine ethanol concentrations. 
Throughout the duration of this study, all mice gained -0.5 g/week, with no 
differences between dietary and treatment groups. Daily urine alcohol 
concentrations cycled between 0 and 500 mg/dl in ethanol-exposed mice, as 
observed previously.14 PKCE ASO- and vehicle-treated mice receiving ethanol 
had similar patterns of urine alcohol cycling, with mean alcohol levels not 
significantly different (284 ± 78 mg/dl versus 217 ± 44 mg/dl for vehicle and ASO 
groups, respectively). In saline-treated mice fed control diet, liver weights (as 
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percent of body weight) were 5.9 ± 0.5 g, whereas ethanol-fed mice had liver 
weights of9.? ± 0.3 g. This doubling in liver weight was not affected by knocking 
down PKCE. 
2. Effect of chronic ethanol exposure on plasma and histological indices of 
liver damage 
Figure 4.1A shows representative photomicrographs depicting liver 
pathology (H+E stain, left column), fat accumulation (oil red 0 stain, middle 
column) and neutrophil infiltration (CAE stain, right column). Figure 4.1 B 
summarizesquantitation of the staining, as well as plasma transaminase values. 
Administration of PKCE ASO to animals fed control diet had no effect on liver 
pathology or plasma transaminases (Figure 4.1 B). Chronic exposure to ethanol 
diet for 4 weeks increased fat accumulation, inflammation, and cell death (Figure 
4.1A, middle row, Figure 4.1 B) as well as increases in plasma transaminases 
(AL T and AST) (Figure 4.1 B, right panel). Coadministration of the PKCE ASO 
partially blunted the hepatic fat accumulation caused by ethanol (Figure 4.1A, 
bottom row, Figure 4.1 B); specifically, the PKCE ASO blunted the increase in 
macrovesicular fat caused by ethanol, but did not significantly alter 
microvesicular fat accumulation. However, the PKCE ASO did not significantly 
attenuate the increases in indices of inflammation and liver damage caused by 
ethanol (Figure 4.1). Indeed, the increase in neutrophils caused by ethanol was 
significantly enhanced (-2-fold) by ASO administration (Figure 4.1 B, left panel). 
In line with these findings, the PKCE ASO did not prevent the increase in 
transaminases caused by ethanol (Figure 4.1 B, right panel). 
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3. Effect of ethanol on hepatic DAG 
Some of the major activators of PKC£ are diacylglycerols (DAG).18 
Therefore, the effect of chronic ethanol on hepatic DAG content was determined 
(Figure 4.2). Figure 4.2 shows representative mass chromatograms from mice 
fed control- and ethanol-containing diet. In general, most DAG species were 
increased by ethanol. For example, chronic ethanol significantly increased 
hepatic content of DAG 36:4 from 129 ± 26 pmoles/mg wet weight to 346 ± 66 
pmoles/mg wet weight. Likewise, ethanol exposure increased the amount of 
DAG 36:3 from 72 ± 4 pmoles/mg wet weight to 289 ± 63 pmoles/mg wet weight. 
4. Chronic ethanol activates PKCE 
Figure 4.3 shows the effect of chronic ethanol on protein and mRNA levels 
of PKC£. As stated previously, a recent study completed by this group 
demonstrated that acute ethanol increases the ratio of membrane to cytosolic 
PKC£ (Chapter 111),91 which is indicative of increased activation. Therefore, the 
effect of chronic ethanol on this index of PKC£ activation was determined in 
Figure 4.3 (upper panel). Ethanol exposure significantly increased (-S-fold) 
PKC£ membrane localization compared to controls (Figure 4.3, lower left panel). 
As expected, administration of the PKC£ ASO decreased protein levels in both 
compartments. Figure 4.3 (lower right panel) shows the effect of ethanol on 
mRNA levels of PKC£. Ethanol alone had no effect on PKC£ mRNA expression 
compared to control mice that received vehicle. In line with the Western data, 
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ASO treatment significantly decreased PKCE mRNA levels to about 20% of 
controls, irrespective of diet treatment (Figure 4.3, lower right panel). 
5. Effect of knocking down PKCE on changes in hepatic lipids caused by 
ethanol 
Histological indices of lipid accumulation (see Figure 4.1) indicated that 
ethanol-induced steatosis was blunted by the PKCE ASO. The effect of the PKCE 
ASO on the increases in specific hepatic lipid pools (triglycerides, FFA, 
cholesterol, and phospholipids) was therefore determined. Figure 4.4 shows 
various parameters of lipid accumulation caused by ethanol. Chronic ethanol 
caused significant increases in triglycerides, FFA, cholesterol, and phospholipids 
(Figure 4.4). The PKCE ASO partially increased cholesterol and phospholipids in 
control-fed mice (Figure 4.4C and D). Furthermore, ASO treatment partially 
prevented the ethanol-induced increases in triglycerides, FFA, and phospholipids 
(Figure 4.4). It has been shown that some species of fatty acid (Le. palmitic acid) 
can mediate toxic effects in liver cells.93 Therefore, a change in total FFA (Figure 
4) may not yield information about specific fatty acids of interest. The effect of 
ethanol and the PKCE ASO on the spectrum of fatty acids was therefore 
determined by gas chromatography/mass spectrometry (Figure 4.5). Ethanol 
caused robust increases in all species of fatty acids analyzed compared to 
control-fed animals. While not able to blunt the accumulation of all species, the 
PKCE ASO blunted (-50%) the increases in palmitic (16:0) and oleic (18:1 n-9) 
(Figure 4.5). 
65 
6. Effect of ethanol on key genes 
One of the major genes responsible for de novo fatty acid synthesis is 
fatty acid synthase (FAS); this gene has also been shown to contribute to 
ethanol-induced lipid accumulation.94 To determine if FAS induction could be in 
part responsible for the observed effects of the PKC£ ASO under these 
conditions (Figure 4.48), FAS expression was determined by real-time rtPCR 
(Figure 4.6A). Chronic ethanol significantly increased (-4-fold) FAS mRNA 
levels and this increase was completely attenuated by ASO treatment (Figure 
4.6A). Previous studies have demonstrated a key role of TNFa in experimental 
ALD; for example, TNFR1 knockout mice are almost completely protected 
against chronic alcohol-induced liver damage.41 Furthermore, TNFa has been 
shown to increase FAS levels.95 Ethanol robustly increased (-3-fold) TNFa 
expression, and this upregulation was almost completely attenuated by knocking 
down PKC£ (Figure 4.68). Recent studies have also identified a role of PAI-1 in 
experimental liver damage caused by chronic ethanol.21 Therefore, the effect of 
chronic ethanol on the expression of this gene was tested (Figure 4.6C). As has 
been observed previously,21 four weeks of enteral ethanol exposure significantly 
increased (-4-fold) PAI-1 expression. In contrast to its effect on TNFa, 
coadminstration of the PKC£ ASO had no effect on the increase in PAI-1 
expression caused by ethanol (Figure 4.6C). 
7. Effect of chronic ethanol on hepatic fibrin deposition 
It was previously shown that PAI-1 contributes to inflammatory liver 
damage caused by chronic ethanol exposure.21 Previous work has also 
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demonstrated that the inhibition of fibrin degradation by PAI-1 contributes to 
hepatic inflammation.21 , 96, 97 Since the induction of PAI-1 was not attenuated by 
the PKC£ ASO (Figure 4.6C), the effect of chronic ethanol on hepatic fibrin 
deposition was determined. Figure 4.7 comprises representative confocal 
photomicrographs depicting immunofluorescent detection of fibrin deposition. 
Chronic enteral ethanol increased fibrin deposition in sinusoidal spaces of the 
liver lobule (Figure 4.7). In line with PAI-1 expression results (Figure 4.6C), 
PKC£ ASO treatment did not affect this increase in fibrin deposition caused by 
ethanol (Figure 4.7). 
D. Discussion 
It was previously determined that PKC£ plays a critical role in acute 
ethanol-induced steatosis (Chapter 111).91 However, chronic ALD is actually a 
series of pathologies (e.g. inflammation, necrosis, etc.) that mayor may not be 
mechanistically related. Therefore, it is important to determine the role of PKC£, 
not only in steatosis, but also in later more severe stages of ALD. Therefore, the 
goal of this work was to investigate the role of PKC£ in a model of chronic ALD. 
The 'two-hit' hypothesis implies that preventing steatosis should blunt more 
advanced liver damage (e.g., inflammation and necrosis).27,98 Since the 
inhibition of PKC£ prevented acute ethanol-induced steatosis (Chapter III), it was 
hypothesized a priori that this effect on steatosis would also protect against 
inflammation and necrosis caused by chronic ethanol exposure. Surprisingly, 
whereas PKC£ ASO-treatment indeed blunted steatosis caused by chronic 
ethanol, it provided no protection against inflammation or necrosis (Figure 4.1). 
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Ethanol exposure causes steatosis via increases in synthetic pathways of 
lipids as well as decreases in catabolic pathways. For example, ethanol induces 
FAS expression and activity (synthetic) and concomitantly inhibits the ~-oxidation 
(catabolic) of fatty acids.85, 94 Here, the increase in FAS expression caused by 
ethanol was almost completely attenuated in ASO-treated mice that received 
ethanol (Figure 4.6). This downregulation of FAS by the ASO correlated with a 
decrease in lipid (Le. triglycerides, FFA, and phospholipids) accumulation caused 
by ethanol (Figure 4.4). Therefore, these data suggest that under these 
conditions, the increase in lipid accumulation caused by ethanol is mediated, in 
part, by the indirect upregulation of FAS via PKCE. Although, there is no 
evidence that PKCE directly influences FAS expression, it has been shown that 
TNFa increases FAS levels in rodent liver.95 Furthermore, previous studies have 
shown that PKCE mediates the upregulation of TNFa expression caused by LPS 
exposure in liver.99 Here, the increases in mRNA levels of TNFa caused by 
ethanol were significantly blunted by ASO treatment (Figure 4.6). Therefore, the 
PKCE ASO may be blunting FAS induction indirectly by preventing the induction 
of TN Fa. 
As mentioned in the Introduction of this chapter, steatosis is hypothesized 
to be a key step in ALD.9 Furthermore, conditions that blunt steatosis generally 
blunt later stages of experimental ALD.100 It was therefore somewhat surprising 
that even though the PKCE ASO was able to significantly attenuate fatty liver 
caused by alcohol, more severe liver injury was unaffected. Such a finding, 
however, is not without precedent. For example, Yamaguchi et al. 101 showed 
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that in a methionine-choline deficient mouse model, the inhibition of 
diacylglycerol acyltransferase 2 (DGAT2) prevented steatosis, but actually 
exacerbated inflammation and liver damage. The increase in liver injury in that 
study was attributed to the accumulation of toxic free fatty acids that no longer 
enter into triglyceride synthesis. Here, such an increase in fatty acids 101 was not 
observed in the PKC£ ASO group. Indeed, there was a general decrease in this 
lipid pool (Figure 4.4). Furthermore, the ethanol-induced increase in fatty acids 
known to be hepatotoxic (e.g. palmitic acid102) was actually blunted by the PKC£ 
ASO (Figure 4.5). It is therefore unlikely that the effects observed here can be 
explained via the mechanisms identified in those previous studies. 101 , 102 
A previous study determined that a high fat diet with cholesterol can cause 
inflammation with little or no steatotic response. 103 Specifically, it was 
determined that LDLR-deficient and apolipoprotein E2 overexpressing mice fed a 
high fat cholesterol diet did not have increased triglyceride content compared to 
control mice, but the diet did increase the number of inflammatory foci. In that 
study, the authors propose that a diet high in cholesterol increases plasma low-
density lipoproteins, triggering a hepatic inflammatory response. 103 Furthermore, 
previous studies have shown that accumulation of mitochondrial cholesterol can 
be hepatotoxic. 104 These mechanisms could in principle provide an explanation 
for the results obtained here, as it was determined that chronic ethanol caused a 
significant elevation in cholesterol that was not attenuated by the PKC£ ASO 
(Figure 4.4C). However, the increase in hepatic cholesterol associated with liver 
'damage in that study 103 was far more than the -2-fold increase observed here 
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(Figure 4.4C). Nevertheless, the potential role of cholesterol accumulation under 
these conditions cannot be dismissed. 
In a recent study performed by this group, it was determined PAI-1 is 
involved in the sensitization of ethanol preexposure to LPS-induced inflammation 
and liver damage.97 PAI-1 has been shown in studies completed by this group 
and others to contribute to hepatic inflammation.21 , 51, 97,105 One main function of 
PAI-1 is to impair fibrinolysis, which is hypothesized to mediate the inflammatory 
effects of PAI-1 upregulation.96 For example, it was shown that fibrin matrices 
are permissive to chemotaxis and activation of monocytes and leukocytes.106, 107 
In that study,97 PAI-1 inhibition blocked fibrin deposition, as well as the liver 
damage. These results suggest that the fibrin accumulation plays an important 
role in sensitizing the liver to LPS-induced damage. Under the current 
conditions, chronic ethanol upregulated PAI-1, which was unaffected by the 
PKC£ ASO (Figure 4.6). Chronic ethanol also caused a robust accumulation of 
fibrin, which could not be attenuated by the PKC£ ASO (Figure 4.7). The inability 
of the PKC£ ASO to prevent fibrin accumulation could explain why the PKC£ 
ASO blocked steatosis but had no effect against inflammation. 
Taken together, the results of this work provide further support for the role 
of PKC£ in ethanol-induced steatosis. Furthermore, this study determined that 
knocking down PKC£ does not prevent inflammation, most likely by failing to 
prevent the induction of PAI-1 caused by ethanol. Therefore, this work gives 
further support to the proinflammatory role of PAI-1 in liver, potentially via its 
ability to block fibrin degradation. These data also suggest that therapies that 
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block steatosis may be ineffective in preventing liver injury if they do not regulate 
inflammatory mediators, such as PAI-1. 
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Figure 4.1: Effect of PKCE deficiency on chronic ethanol-induced liver 
damage 
Panel A, representative photomicrographs of hematoxylin and eosin 
[(H+E, left panel, 100x) (inserts are 400x)], oil red 0 [(middle panel, 100x (inserts 
are 400x)] and chloroacetate esterase (CAE, right panel, 100x) staining are 
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Figure 4.2: Effect of acute ethanol on hepatic DAG and levels 
Positive electron spray ionization mass spectrums are shown from liver 
extracts. Since Na+ adducts were used to detect DAG species, the m/z value 
represents the molecular weight of the respective DAG plus the weight of a 
sodium molecule (M+Na+). Representative chromatograms of livers from control 






























Figure 4.3: Effect of chronic ethanol on the activation of PKCE in mouse 
liver 
Representative Western blots (upper panel) are shown depicting the 
membrane and cytosolic fractions of PKCE and quantitated by image-analysis 
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Figure 4.4: Effect of chronic ethanol on indices of hepatic lipid 
accumulation 
Quantitations of lipids were determined in hepatic extracts via colorimetric 
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Figure 4.5: Effect of chronic ethanol on specific free fatty acid species 
Representative gas-liquid chromatography profiles of fatty acid methyl 
esters are shown from liver extracts after direct transesterification. Labeled 
peaks by retention times (RT) have been identified to a known free fatty acid. 
Summary data is shown in tabular format for select species (lower panel). N/A 
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Figure 4.6: Effect of ethanol on expression of key genes 
The effect of ethanol and ASO on the expression of fatty acid synthase 
(FAS; Panel A), tumor necrosis factor a (TNFa; Panel B), and plasminogen 
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Figure 4.7: Effect of ethanol on fibrin deposition 
Representative confocal photomicrographs (400 X) depicting 





PKCE PLAYS A CRITICAL ROLE IN CCL4-INDUCED FIBROSIS 
86 
A. Introduction 
One of the common pathological changes in response to chronic liver 
damage is accumulation of extracellular matrices (ECM) leading to fibrosis. 108 
Fibrosis can eventually lead to cirrhosis; once cirrhosis ensues, the inflicted 
person may die without a liver transplant. 52 In a previous study performed in 
humans, it was shown that liver fibrosis and cirrhosis can partially repair if the 
underlying cause is successfully treated (e.g. hepatitis virus C infection).43 
However, there is no FDA approved therapy to stop the progression of fibrotic 
liver disease due to the incomplete understanding of the mechanisms underlying 
hepatic fibrosis. 
In previous studies by this group, it was determined that PKCE plays a 
causal role in both experimental acute and chronic ethanol-induced steatosis, 
most likely by disrupting hepatic lipid metabolism (Chapter III and IV).91 The next 
pathological step in ALD is steatohepatitis which is comprised of inflammation 
and necrosis. Studies performed by this group have shown that PKCE ASO 
treatment provided no protection against chronic ethanol-induced steatohepatitis 
due to the proinfammatory protein, PAI-1 being independent of PKCE activation 
(Chapter IV). Following steatohepatitis, the next pathological step in ALD is 
fibrosis, which is basically the scarring of the liver. Whereas data for the role of 
PKCE in hepatic fibrosis is lacking, past studies have shown that PKCE 
contributes to fibrosis in the heart via the upregulation of TGF~-1, leading to ECM 
secretion and the subsequent fibrosis. 61 Although unknown, it could be possible 
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that PKCE causes hepatic fibrosis via a similar mechanism as described in the 
heart. 
Although evidence for a role of PKCE in hepatic fibrosis is lacking, it has 
been determined that PKCE is activated by compounds that lead to hepatic 
fibrosis. Specifically, a study performed in rats determined that CCI4 and 
thioacetamide, chemical agents known to cause hepatic fibrosis, significantly 
activate PKCE, and the activation of this kinase precedes the morphological 
changes (i.e. fibrosis).109 It may be possible that upon activation by one of these 
fibrosis causing chemicals, PKCE could playa role in the conversion of the liver 
to a profibrotic state.109 Therefore, the purpose of this study was to test the 
hypothesis that PKCE plays a causal role in hepatic fibrosis owing to CCI4 
administration. 
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B. Materials and Methods 
1. Animals and treatments 
Mice were treated with CCI4 as described in Chapter II. 
2. Immunoblotting 
Western Blotting comparing the membrane and cytosol fractions was done 
as described in Chapter II. 
3. Histological Analysis 
See Chapter II for detailed method. 
4. Clinical Chemistry 
See detailed method in Chapter II. 
5. RNA isolation and Real-Time PCR 
See detailed method in Chapter II. 
6. Zymography 
The gelatinase activity of MMP-9 was measured by zymography as 
described in Chapter II 
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C. Results 
1. Effect of chronic CCI4 on plasma and histological indices of liver 
damage and fibrosis 
Figure 5.1 A depicts representative photomicrographs depicting liver pathology 
(H+E, Figure 5.1A, left column) and liver fibrosis (Sirius red Figure 5.1A, right 
column). Chronic exposure of CCI4 caused robust liver damage which was not 
attenuated by the PKC£ ASO (Figure 5.1A, left column). The PKC£ ASO also did 
not prevent the CCl4-induced increase in the plasma transaminases (AST and 
AL T) (Figure 5.1 B, left column). Administration of the PKC£ ASO to mice treated 
with olive oil had no effect on liver pathology or plasma transaminases. 
Four weeks of CCI4 treatment also caused hepatic fibrosis as determined 
by Sirius red (Figure 5.1A, right column). Although there was no difference in the 
extent of the ECM deposition between vehicle and ASO-treated mice that 
received CCI4, the PKC£ ASO decreased the septa width of the ECM fibers 
compared to vehicle-treated mice (Figure 5.1A, right column). This effect of the 
ASO significantly decreased (-50%) the Sirius red-positive area of the liver 
caused by CCI4 (Figure 5.1 B, right column). 
2. Chronic CCI4 decreases PKCE activation 
Figure 5.2 shows the effect of chronic CCI4 on the ratio of membrane to 
cytosol ratio of PKC£ and mRNA levels of PKC£. As stated previously, a recent 
study completed by this group demonstrated that acute ethanol increases the 
ratio of membrane to cytosolic PKC£ (Chapter 111),91 which is indicative of 
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increased activation. Therefore, the effect of chronic CCI4 on this index of PKCE 
activation was determined in Figure 5.2 (upper panel). Surprisingly, CCI4 
exposure significantly decreased (-2-fold) PKCE membrane localization 
compared to controls (Figure 5.2, lower left panel). As expected, administration 
of the PKCE ASO dramatically decreased protein levels in both compartments. 
Figure 5.2 (lower right panel) shows the effect of CCI4 on mRNA levels of PKCE. 
CCI4 alone downregulated PKCE mRNA expression compared to control mice 
that received vehicle. In line with the Western data, ASO treatment significantly 
decreased PKCE mRNA levels to about 20% of controls (Figure 5.3, lower right 
panel). 
3. Effect of CCI4 on pro-fibrotic genes 
Increases in mRNA levels of TGFI3-1, aSMA, and collagen la1 are 
measures of stellate cell activation and ECM synthesis. Furthermore, it has been 
shown that experimental models that cause hepatic fibrosis, also upregulate PAI-
1.51 Therefore, the effect of CCI4 on the expression of these genes was 
determined by real-time rtPCR. CCI4 significantly increased the mRNA levels of 
all of these genes compared to control mice (Figure 5.3). Specifically, chronic 
exposure of CCI4 significantly upregulated TGFI3-1 (-1.5 fold) compared to 
controls. The PKCE ASO partially blunted the increase in this gene in both CCI4-
and olive oil-treated mice (Figure 5.3A). CCI4 also enhanced the expressions of 
aSMA and collagen la1; the PKCE ASO significantly blunted the increase in 
aSMA but not collagen la1 (Figure 5.38 and C). PAI-1 was also significantly 
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upregulated by CCI4, the increase in mRNA levels of this gene by CCI4 was 
attenuated by the knockdown of PKCE (Figure 5.30). 
4. CCI4 increases stellate cell activation and hepatic fibrin deposition 
In Figure 5.3, it was determined that the upregulation of aSMA expression 
by CCI4, an index of stellate cell activation, was blunted by ASO treatment 
(Figure 5.38). To further establish the role of PKCE in activating stellate cells, 
immunohistochemical staining for aSMA was performed (Figure 5.4, left panel). 
Chronic CCI4 exposure caused a robust increase in aSMA staining which was 
partially blunted by the PKCE ASO treatment (Figure 5.4, left panel). 
Whereas collagen I is the prominent ECM accumulated during fibrosis, 
there are many other types of ECM such as laminin, proteoglycan, and fibrin that 
also accumulate and lead to the pathological changes associated with fibrosis.45 
In previous studies, plasmin has been shown to playa major role in the 
regulation of ECM accumulation by directly degrading types of ECM like laminin 
and fibrin. 47-49 PAI-1 plays a major role in fibrinolysis by inhibiting the conversion 
of plasminogen to plasmin.2o In support of this, it was recently demonstrated that 
impaired fibrin degradation owing to PAI-1 contributes to hepatic inflammation.21 , 
96, 97 The effect of chronic CCI4 on hepatic fibrin deposition was therefore 
determined. Figure 5.4 (right panel) comprises representative confocal 
photomicrographs depicting immunofluorescent detection of fibrin deposition. 
Chronic CCI4 increased fibrin deposition in sinusoidal spaces of the liver lobule. 
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PKCE ASO treatment partially blunted the increase in fibrin deposition caused by 
CCI4 (Figure 5.4, right panel). 
5. Effect of CCI4 on MMP-9 activity 
ECM deposition is regulated not only at the level of synthesis (e.g. stellate 
cell activation) but at the level of degradation as well by MMPs for example. In a 
previous study performed by this group, it was shown that PAI-1 knockout mice 
were protected from SDL-induced liver fibrosis, most likely owing to an increase 
in MMP-9 activity. 51 Therefore, the effect of CCI4 on MMP-9 was determined 
(Figure 5.5). Chronic CCI4 significantly increased activation of MMP-9 (-2.5-fold) 
compared to controls and this effect was not affected by PKCE ASO treatment 
(Figure 5.5). 
D. Discussion 
The major findings of this chapter demonstrate that PKCE mediates 
hepatic fibrosis in a mouse model of chronic CCI4 exposure. Specifically, it was 
determined that mice treated with an ASO to knockdown PKCE, had less ECM 
accumulation as determined by Sirius Red staining compared to vehicle-treated 
mice receiving CCk This ability of the PKCE ASO to partially block fibrosis 
correlated with a blunting of the upregulation of aSMA, an index of hepatic 
stellate cell activation, and of PAI-1, a major regulator of fibrinolysis. 
Furthermore, this protective effect of the PKCE ASO seems to be mediated 
primarily at the level of fibrosis as the early onset of hepatic inflammation and 
liver damage caused by CCI4 was not abrogated by knocking down PKCE. 
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As mentioned previously, previous studies have determined that PKC£ 
contributes to cardiac fibrosis. 61 Whereas no studies have investigated the role 
of PKC£ in hepatic fibrosis, results have shown a correlation between PKC£ 
activation and CCl4-induced liver fibrosis. 109 From these results, it could be 
hypothesized that PKC£ may induce changes (e.g. stellate cell activation, 
upregulation of profibrotic cytokines, etc.) in the liver that result in the 
development of fibrosis. The data presented in the current study support this 
hypothesis by demonstrating a causal role of PKC£ in the formation of fibrosis 
owing to CCI4. 
How does PKC£ cause fibrosis? 
One of the surprising results of this study is that four weeks of CCI4 
exposure actually decreased the activation of PKC£ (Figure 5.2). However, this 
effect of chronic CCI4 on PKC£ is not without precedence. Specifically, studies 
have shown that CCI4 causes a cyclic pattern in the activation of PKCs and that 
activation of PKC£ precedes the onset of fibrosis followed by the deactivation of 
the kinase at the peak fibrotic/cirrhotic changes. 109 
The formation of fibrosis is generally thought to be due to the 
overproduction of ECM and/or impairment in the degradation of these proteins. 
One mechanism that can lead to an overproduction of ECM is the transformation 
of stellate cells to myofibroblasts which then produce and secrete collagen and 
other types of ECM. To determine if PKC£ was mediating hepatic fibrosis at this 
level, the expression of aSMA, an index of stellate cell activation, was 
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determined under these conditions (Figure 5.38). As expected, chronic CCI4 
significantly upregulated aSMA and this effect was partially blunted by the PKCE 
(Figure 5.38). This blunting of aSMA by the PKCE ASO was also verified by 
histological assessment (Figure 5.4, left panel). Therefore, it is likely that the 
knockdown of PKCE partially prevents fibrosis, in part by preventing the activation 
of stellate cells and their subsequent conversion to myofibroblasts. 
Of the many profibrotic cytokines (e.g. VEGF, PDGF, etc.) that activate 
hepatic stellate cells, TGF~-1 represents the major causal player of stellate cell 
activation in the liver.42 In support of the role of TGF~-1 in activating stellate cells 
and causing fibrosis, many compounds that block fibrosis also blunt the 
upregulation of TGF~-1.61 Under the current conditions, chronic CCI4 
significantly increased mRNA levels of TGF~-1 and this effect was partially 
blunted by the PKCE ASO (Figure 5.3C). Therefore, the activation of hepatic 
stellate cells by PKCE is most likely mediated by TGF~-1. In support of this, a 
previous study determined that a PKCE blocker blunts cardiac fibrosis by 
inhibiting TGF~-1 and the subsequent ECM accumulation.61 
Hepatic fibrosis is associated with an excess of ECM accumulation in the 
liver. Whereas the production of ECM by myofibroblasts is a major cause of 
fibrosis, it is not the sole mechanism of this pathology. Many studies have shown 
a strong correlation between impaired ECM degradation and liver fibrosis and 
that the balance between enzymes that degrade ECM (e.g. MMPs) and the 
inhibitors of these enzymes (e.g. TIMPs) is critical in the progression of fibrosis.45 
A key process in the degradation of ECM is the activation of plasminogen to 
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plasmin by tissue-type plasminogen activator (tPA) and urokinase-type 
plasminogen activator (uPA). The conversion of plasminogen to plasmin plays a 
major role in ECM metabolism as plasmin has been shown to directly degrade 
ECM proteins like fibrin and laminin and indirectly by activating MMPs.47-50 Thus, 
the regulation of the plasminogen activating system is critical in preventing 
hepatitis fibrosis. 
One of the major regulators of the plasminogen activating system is PAI-1. 
Specifically, PAI-1 inhibits the activity of uPA and tPA, thus eliminating the ECM 
degradation properties of plasmin. The casual role of PAI-1 in fibrosis is well 
known and further supported by the positive correlation between hepatic fibrosis 
and PAI-1 expression.11o Furthermore, studies by this group have shown that 
PAI-1 knockout mice are partially protected against fibrosis owing to bile duct 
ligation and this protective effect was likely mediated by an increase in MMP-9 
and uPAltPA activity. Given this profibrotic role of PAI-1 and the fact that PAI-1 
has been shown to be regulated by PKCS,111 the expression of PAI-1 under 
these conditions was determined. As expected, four weeks of CCI4 significantly 
upregulated PAI-1 and this effect was partially blunted by knocking down PKCE 
(Figure 5.3D). Mentioned previously, the ECM that accumulates in fibrosis is 
comprised not only of collagen but other matrix proteins as well such as fibrin. 
By blocking the conversion of plasminogen to plasmin, PAI-1 prevents the 
degradation (i.e. fibrinolysis) of fibrin, causing its accumulation thus contributing 
to fibrosis.112 To determine if the protective effect of the PKCE ASO against 
fibrosis could be mediated by preventing the PAI-1-induced impairment of matrix 
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degradation, the effect of CCI4 on fibrin accumulation was determined (Figure 
5.4, right panel). CCI4 caused a robust accumulation of fibrin in the liver, which 
was partially blunted the PKC£ ASO. These data therefore suggest that PKC£ 
may contribute to fibrosis by upregulating PAI-1, which subsequently impairs 
matrix degradation processes such as fibrinolysis, leading to fibrosis. 
Does fibrin accumulation contribute to the complications associated with 
cirrhosis? 
Mentioned above, fibrosis is considered the last phase of alcoholic liver 
disease before the development of cirrhosis which will most likely lead to death 
without a liver transplant.52 However, mortality with a cirrhotic patient is not due 
to cirrhosis itself but to the secondary effects of the disease such as portal 
hypertension, ascites, esophageal varices for example. These potentially lethal 
side effects of cirrhosis may be due to liver failure itself or could be owing to 
other etiological factors.4 In previous studies, it was shown that accumulation of 
fibrin clots can lead to hemostasis, the conversion of blood from a fluid to a 
solid.113 Hemostasis can cause resistance to blood flow in the hepatic portal 
vein, causing portal hypertension which can then lead to other complications like 
ascite and/or espophageal varices. 114 Mentioned in the Results section of this 
chapter, CCI4 caused a robust accumulation of fibrin in the liver (Figure 5.4). 
Whereas fibrin accumulation may be a pathological trademark of fibrosis, it may 
actually have a more clinical role in causing secondary effects of ALD that result 
in the death of inflicted patients. 
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Figure 5.1: Effect of the PKCE ASO on CCl4-induced liver damage 
Panel A, The effect of CCI4 on liver histology was assessed by hematoxylin and 
eosin [(H+E, left column, 100x) (inserts are 400x)] and Sirius red [(right panel, 100x) 
(inserts are 400x)]. Representative photomicrographs are shown. Panel B, plasma 
transaminases (left column) were determined as described in Chapter II. Intensity of 
Sirius red staining (right column) was assessed by image analysis. Quantitative data 
are reported as means ± SEM, n=4-6. a, p<O.05 compared to absence of CCI4 . b, 
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Figure 5.2: Effect of CCI4 on PKCE activation 
Real-time rtPCR was performed as described in Chapter II, and results 
were normalized to ~-actin. Western blot of PKCE was performed as described in 
Chapter II. Representative blots are shown depicting the membrane and 
cytosolic fractions of PKCE. The data represent means ± SEM (n=4-6). a, p<O.05 
compared to the absence of CCI4 . b, p<O.05 compared to the absence of ASO as 
determined by 2-way AN OVA. 
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Figure 5.3: Effect of CCI4 on the expression of pro-fibrotic genes 
Real-time rtPCR was performed as described in Chapter II, and results 
were normalized to ~-actin. Data are means ± SEM (n=4-6) and are reported as 
fold of control values. a, p<O.05 compared to the absence of CCI4. b, p<O.05 
compared to the absence of ASO as determined by 2-way ANOV A. 
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Figure 5.4: Effect of CCI4 on aSMA and fibrin deposition 
The effect of CCI4 on aSMA accumulation was assessed by 
immunohistochemical staining [(aSMA, left column, 1 OOx) (inserts are 400x)). 
Representative confocal photomicrographs (400 X) depicting immunofluorescent 
detection of hepatic fibrin (green) against a Hoechst counterstain (blue) are 
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Figure 5.5: Effect CCI4 on MMP-9 activity 
Representative zymographs demonstrating gelatin lysis by MMP-9 are 
shown in the upper panel. The lower panels show results of densitometric 
analysis of activity. Data are means ± SEM (n = 4-6) and are expressed as % of 
control values. a, p<O.05 compared to the absence of CCI4. b, p<O.05 compared 
to the absence of ASO as determined by 2-way ANOV A. 
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CHAPTER VI 
SUMMARY AND GENERAL DISCUSSION 
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A. Major Findings of this Dissertation 
The experiments performed in the third chapter of this dissertation were 
designed to test the hypothesis that PKCE plays a causal role in acute ethanol-
induced steatosis. The effects of acute ethanol on PKCE activation and indices 
of insulin signaling were determined, as well as the effect of inhibiting (i.e. 
knockout or knockdown) PKCE on ethanol-induced steatosis. Mentioned 
previously (Chapter I, Section E), the acute model of ethanol exposure employed 
here is a useful screening tool for molecular mechanisms of chronic ethanol-
induced liver damage. Therefore, experiments described in Chapter IV build on 
results of the third chapter and examine the role of PKCE in steatohepatitis owing 
to chronic ethanol exposure. The effects of a PKCE ASO on histological indices 
of hepatoxicity owing to alcohol were determined. The regulation of the PKCE 
ASO on increases in mRNA levels of proinflammatory and lipid metabolism 
genes caused by ethanol was also determined. Chapter V focuses on the role of 
PKCE on CCl4-induced fibrosis, determining the effect of knocking down PKCE on 
the accumulation of ECM and the upregulation of profibrotic genes owing to CCI4. 
Detailed findings of each of these chapters are detailed below. 
1. PKCE plays a causal role in acute ethanol-induced steatosis 
As mentioned in Chapter III, hepatic insulin resistance is a known risk 
factor for hepatic steatosis. This causal role of insulin resistance in fatty liver is 
further supported by studies from this group showing that metformin, an insulin 
sensitizing drug, partially prevents fatty liver owing to acute ethanol.21 
Furthermore, PKCE, a known inducer of insulin resistance, has been 
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demonstrated to contribute to steatosis caused by a high fat diet in the absence 
of ethanol.86 However, the role of this kinase in steatosis caused by alcohol was 
unknown and was the main question of this Chapter III. Experiments were 
designed to determine if PKCE contributes to ethanol-induced steatosis and the 
mechanisms by which PKCE is causing steatosis. 
First, a time course of the effect of ethanol on hepatic free fatty acids, 
DAG, and triglycerides was determined. As observed previously,21 triglycerides 
peaked -12 h after ethanol exposure and free fatty acids and DAG were 
maximum at -1 h. Next, it was determined that the accumulation of hepatic 
triglycerides caused by ethanol was partially blunted the PKCE ASO and in PKCE 
knockout mice. To verify that PKCE was causing steatosis via insulin resistance, 
the effect of ethanol on insulin sensitive genes (GK and G6Pase) was 
determined and found to be modulated by ethanol in a manner indicative of 
insulin resistance, which was further sUbstantiated by an increase in the ratio of 
plasma insulin to glucose caused by alcohol. Furthermore, the protection against 
fatty liver by the PKCE ASO correlated with a blunting of the increase in G6Pase 
caused by ethanol, suggesting that PKCE is indeed causing steatosis by inducing 
insulin resistance. A visual description of this mechanism can be seen in Figure 
6.2. 
The major findings of this chapter are that PKCE contributes to ethanol-
induced fatty liver. This chapter also sheds further light on the role of insulin 
resistance as a possible mechanism working in tandem with alcohol metabolism 
to cause steatosis after ethanol exposure. Finally, this chapter reveals a novel 
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mechanism by which redox inhibition of ~-oxidation of fatty acids owing to 
ethanol, is leading to increased DAG production and PKC£ activation. PKC£ then 
causes ethanol-induced steatosis by impairing insulin signaling. These findings 
and their signifance are further detailed in section B of this chapter. 
2. PKCE plays a critical role in chronic ethanol-induced steatosis but not in 
inflammation or necrosis 
One of the major findings of this dissertation is that PKC£ plays a causal 
role in acute ethanol-induced steatosis (Chapter III). As stated previously 
(Chapter I, section E), the acute model of ethanol exposure is a useful screening 
tool for mechanisms involved in later stages of ALD and therapies that protect 
against experimental acute ethanol-induced liver damage have also been shown 
to attenuate hepatic damage owing to chronic insults.115 Therefore, the goal of 
this chapter was to determine the role of PKC£ in liver injury caused by chronic 
administration of ethanol. As expected, four weeks of intragrastric alcohol led to 
robust hepatoxicity as determined by histological analyses. The PKC£ ASO was 
able to partially prevent fatty liver but had no protective effect against 
inflammation or necrosis. These data suggest that the pathologies of steatosis 
and steatohepatitis may be mechanistically unrelated. 
One of the major themes of liver research is the 'two-hit' hypothesis, which 
implies that preventing steatosis should blunt more advanced liver damage (e.g., 
inflammation and necrosis).27,98 In this chapter, the PKC£ ASO blunted steatosis 
but conferred no protection against hepatic inflammation or necrosis. Therefore, 
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the mechanism(s) responsible for this "disconnect" between steatosis and 
inflammation were investigated. Summarily, it was determined that chronic 
ethanol upregulated the expression of FAS, a major inducer of lipid synthesis, 
which was partially blunted by knocking down PKCE suggesting that PKCE may 
cause steatosis via increasing FAS mRNA levels. The proinflammatory gene 
PAI-1 was also upregulated by chronic ethanol and this effect was not abrogated 
by the PKCE ASO. This PKCE-independent regulation of PAI-1 may explain why 
the PKCE ASO has no effect on inflammation. Mentioned above, PAI-1 has been 
shown to cause inflammation in various studies. 21,51,97,105 This proinflammatory 
role of PAI-1 is hypothesized to be due to PAI-1 impairing fibrinolysis, as fibrin 
clots have been shown to be permissive to chemotaxis and to activation of 
monocytes and leukocytes. 96, 106,107 Under these conditions, chronic ethanol 
caused a robust accumulation of fibrin, which was not attenuated by the PKCE 
ASO, suggesting that inflammation under these conditions can most likely be 
attributed to the impairment of fibrinolysis by PAI-1, which is independent of 
PKCE activation (see scheme of hypothesized mechanism in Figure 6.3). 
The major finding of this chapter is that the prevention of steatosis does 
not necessarily correlate with protection against inflammation. However, this 
finding is not unique as other studies have demonstrated similar results. For 
example, Yamaguchi et al. 101 determined that the inhibition of diacylglycerol 
acyltransferase 2 (DGAT2) prevented steatosis, but not inflammation and liver 
damage. These data suggests that the validity of the two-hit hypothesis may 
depend on the role of the respective gene that is being targeted to prevent ALD. 
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The deletion of a gene that only plays a part in the steatotic component of ALD, 
may not protect against the further stages (i.e. inflammation, fibrosis etc.). 
Furthermore, Chapter IV gives further support to the steatotic role of PKCE and to 
PAI-1 being proinflammatory. Finally, a therapy may only be effective in treating 
ALD if it targets mediators of inflammation like PAI-1. 
3. PKCE causes hepatic fibrosis 
The finding that PKCE did not contribute to inflammation (Chapter IV) was 
a surprising, suggesting that this kinase may not playa role in later stages (e.g. 
steatohepatitis, fibrosis, etc) of ALD. However, previous studies have shown that 
PKCE contributes to fibrosis in other organs (heart, lung etc.}.61, 116 Furthermore, 
results have shown that PKCE is activated in a rat model of CCl4-induced liver 
fibrosis.109 Therefore, the main objective of Chapter V was to test the role of 
PKCE in hepatic fibrosis owing to chronic administration of CCI4, In short, CCI4 
caused a robust accumulation of ECM in the liver which was partially attenuated 
by the knockdown of PKCE. 
It was previously determined in rats that the activation of PKCE by CCI4 
precedes the onset of hepatic fibrosis, and it was therefore hypothesized that 
PKCE may playa role in the development of this pathology.109 However, this 
hypothesis had not been directly tested. Results from Chapter V of this 
dissertation directly support this hypothesis. The ability of the PKCE ASO to 
prevent fibrosis correlated, with attenuated upregulation of profibrotic genes 
induced by CCI4 exposure. The increase in stellate cell activation, as determined 
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by aSMA expression, was also blunted by knocking down PKC£, suggesting that 
this kinase plays a causal role in the transdifferentiation of quiescent stellate cells 
to myofibroblast-like cells. Furthemore, the PKC£ ASO abrogated the rise in 
mRNA levels of TGFrJ-1, a known inducer of hepatic stellate activation.42 
Therefore, it is likely that TGFrJ-1 serves as the catalyst for stellate activation 
owing to PKC£ under these conditions. Finally, the ability of the ASO to block 
PAI-1 induction suggests that PKC£ contributes to fibrosis, in part, by indirectly 
impairing the plasminogen activation system, leading to a decreased degradation 
of ECM. Figure 6.4 contains a detailed schematic regarding the role of PKC£ in 
CCl4-induced fibrosis. 
The onset of fibrosis can divided into two broad categories: initiation and 
progression. The iniation phase consists of cellular events that allow quiescent 
stellate cells to be more readily activated by growth factors (e.g. PDGF, VEGF, 
TGFrJ-1 etc). This senisitization of stellate cells is accompanied by an increase 
in growth factor signaling like TGFrJ-1 for example. The progression stage, also 
known as perpetuation, is highlighted by the activation of stellate cells (via growth 
factors), conversion of these cells to myofibrobast-like state, ECM secretion from 
stellate cells, and impaired matrix degration.42 
The most significant finding of this chapter is that PKC£ appears to be 
causing hepatic fibrosis both at the level of initiation and progression. This 
causal role of PKC£ in hepatic fibrosis correlates with other studies that 
determined a similar role of PKC£ in other organs.51 , 115 In Chapter V, PKC£ 
upregulated TGFrJ-1 (i.e. initiation phase) which then activates stellate cells (i.e. 
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progression stage). Under these conditions, PKCE further contributed to fibrosis 
by decreasing the plasminogen activation system by upregulating PAI-1, leading 
to impaired matrix degradation (i.e. progression stage). Therefore, it could be 
suggested that PKCE is causing fibrosis at the initiation level (TGF~-1 
upregulation) as well as the progression phase by activating stellate cells via 
TGF~-1 and by impairing the degradation of ECM that are secreted by stellate 
cells upon their activation. 
B Significance of this Study 
As mentioned throughout this dissertation, ALD is a major disease with no 
FDA approved therapy for treatment. This lack of treatment is in part, due to an 
incomplete understanding of the mechanisms behind the pathologies associated 
with ALD. This dissertation provides detailed mechanisms of the involvement or 
lack thereof in different pathologies (steatotitis, inflammation, and fibrosis). 
Therefore, the finding that PKCE contributes to ALD is crucial in that it provides 
further mechanistic insight into ALD and reveals a new possible therapeutic 
target in ALD treatment. 
The role of PKCE in ALD, specifically in steatosis, may answer questions 
in the liver research field that have been unknown for over 30 years. Specifically, 
as described in Chapter I, a long standing hypothesis of ALD is the increase in 
alcohol metabolism directly contributes to liver injury caused by alcohol 
administration.85 However, therapies (e.g. inhibiton of iNOS, NADPH oxidase, 
etc) that block alcohol-induced steatosis are ineffective in preventing the rise in 
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alcohol metabolism, implying that some other factor(s) are working in tandem 
with alcohol metabolism to induce steatosis. 13, 14 One possible mechanism that 
could be collarobating with alcohol metbalism to cause steatosis is insulin 
resistance due to the ability of metformin, an insulin sensitizing agent, to prevent 
ethanol-induced steatosis. 21 Interstingly, genes that are known to cause fatty 
liver owing to ethanol exposure, such as iNOS and NADPH oxidase, while having 
no role in increasing alcohol metabolism have been shown to cause impaired 
muscular insulin signaling.117, 118 Furthermore, protection against steatosis by 
the PKCE ASO correlated with a blocking of insulin resistance. These data along 
with other studies showing that some genes (e.g. iNOS,NADPH oxidase, etc) 
playa role in both steatosis and insulin resistance, suggests that insulin 
resistance, due to PKCE activation under these condtions, and alcohol 
metabolism may be working together to cause steatosis. Therefore, the 
identification of PKCE as a causal player in ethanol-induced steatosis and hepatic 
insulin resistance may fill voids in our knowledge of ALD mechanisms that have 
been present for over three decades. 
ALD and Type II diabetes are closely related diseases in that they have 
pathological and mechanistic traits in common. One of the major characteristics 
of Type II diabetes is insulin resistance, which is known to contribute to ALD.18 
Furthermore, Type II diabetes and ALD share some pathological similarities, 
such as steatosis and steatohepatitis. Also, people with type II diabetes have a 
higher risk of developing ALD than people without diabetes. 119, 120 Liver disease 
is also one of the leading causes of death in patients inflicted with type II 
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diabetes. 121 However, the link between the two diseases (ALD and type II 
diabetes) is not a novel idea. For example, metfomin, a therapy used quite 
commonly in type II diabetes, was previously tested in patients with ALD.122. 123 
Whereas metformin was beneficial in a mouse model of steatohepatitis,21 the use 
of metformin in patients with ALD had serious drawbacks as ethanol 
consumption was shown to exacerbate the risk of lactic acidosis by metformin, 
which suggests that metformin may not be an optimal drug to treat ALD.122. 123 In 
Chapter III of this dissertation, it was determined that PKC£ contributes to insulin 
resistance and steatosis caused by acute ethanol exposure. It may be therefore 
possible that PKC£ plays a similar role in the steatotic component of Type II 
diabetes. Therefore, the therapeutic targeting of this kinase may confer 
beneficial effects against both diseases hopefully without the negative side 
effects observed with metformin for alcoholics. 
c. Strengths and Weaknesses of this Dissertation 
1. Strengths 
There are many strengths to this dissertation. First, it identifies a new 
player (PKC£) in alcoholic liver disease and details mechanisms by which this 
kinase participates in various stages of liver disease. Second, there has been 
much debate about the contribution of insulin resistance in causing steatosis. 
This dissertation further supports this link by showing that PKC£ causes ethanol-
induced steatosis potentially by inducing insulin resistance. Lastly, this work 
further solidifies the role of PAI-1 in ALD and suggests that a proper therapy for 
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treating ALD may only be effective if it is successful in preventing the later more 
severe stages (e.g. steatohepatitis, fibrosis, etc). 
A specific strength of this dissertation is the use of an ASO to determine 
the role of PKCE in liver damage. Whereas knockout mice are a useful tool, the 
lifelong deletion of a gene in the development stage of a mouse could result in 
nonspecific effects like the induction of compensatory mechanisms, thus 
emphasizing the need to pharmacologically (e.g ASO, peptide inhibitor, etc.) 
inhibit a target of interest. 124 Conversely, ASOs are highly specific to the liver 
and do not result in a lifelong deletion of a gene that could cause compensatory 
physiology.67 
A preliminary study determined that PKCE knockout mice were partially 
protected against acute ethanol-induced steatosis. To determine if these results 
were due to a compensatory mechanism owing to the lifelong deletion of PKCE, 
an ASO specific to PKCE was used to validate these results. In correlation with 
the data using the knockout mice, PKCE ASO-treated mice were protected to a 
similar degree against ethanol-caused fatty. Therefore, using both methods 
(knockout and ASO) provides strong weight-of-evidence that PKCE contributes to 
steatosis owing to acute ethanol. 
Another strength of this work is the use of whole animals (Le. mice) to 
investigate mechanisms of ALD. The entirety of this research performed was 
completed using in vivo animal models. ALD is a chronic disease involving 
multiple organs and various cell types (see Figure 6.1 for illustration 125). 
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Therefore, whereas cell culture experiments are useful, whole body experiments 
(e.g. in vivo models) are more suitable to fully understand the effects of multiple 
organs and cell types on ALD, allowing for the results of these studies to be 
better translated to the human disease. 
One type of in vivo model of ALD is the Tsukamoto and French 
intragastric chronic ethanol model. Compared to other models (e.g. ad libitum 
feeding) of chronic ethanol, this model bypasses the natural aversion of mice to 
alcohol by intragastric feeding and therefore results in much higher 
concentrations of alcohol, comparable to what is observed in the human disease. 
The high ethanol levels achieved in the Tsukamoto and French model result in 
many of the pathologies observed in human alcoholic liver disease like steatosis, 
inflammation, pericentral necrosis, and fibrosis. Therefore, the employment of 
this model allows for the progression of liver damage owing to ethanol to be 
investigated in a clinically-relevant rodent model. 
2. Weaknesses 
The main focus of this dissertation was the investigation of PKCE in ALD, 
mainly due to its role in hepatic insulin resistance and the contribution to non-
alcoholic fatty liver. However, as stated in Chapter 1 (section E), there are many 
other isoforms of PKC that potentially can play similar roles (i.e. insulin 
resistance, collagen production, etc.) as PKCE. One of the limitations in 
researching individual PKCs is the lack of specific inhibitors. It may very well be 
possible that other types of PKC are working in tandem with PKCE to cause 
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ethanol-induced steatosis for example. This could explain why the PKC£ ASO is 
only able to partially blunt fatty liver caused by alcohol exposure (see Chapter 3, 
Figure 6). Therefore, it could be very beneficial to study different PKCs beside £ 
in mechanisms of ALD. It was fortunate for this study that a PKC£ ASO was 
readily available. If ASOs are designed for other PKC isozymes, it would be 
interesting to determine the role of these other isotypes in models (e.g. acute 
ethanol, chronic ethanol, etc.) of liver damage employed here. 
A second weakness of this dissertation is the use of a chronic model (i.e. 
Tsukamoto and French model) to investigate the role of PKC£ in hepatic 
inflammation. Whereas the chronic intragastric model of ethanol exposure has 
its advantages (see Chapter 1, section E for further detail), it is not without 
drawbacks. Specifically, this chronic model of ethanol exposure, due to 
mechanisms unknown, does not cause fibrosis in rodents. Also, a requirement of 
this model is forced feeding (e.g. intragastric feeding tube) due to a rodents' 
aversion to alcohol; a situation that does not apply to humans. Furthermore, 
Tsukamoto and French ethanol model delivers a nutritional complete diet to 
mice. It is likely that alcoholics consume diets that are of lesser quality and not 
adequate nutritionally. This difference in diets between mice fed ethanol 
intragastrically and human alcoholics coupled with the forced feeding of ethanol 
to mice, highlight the inadequacies of the Tsukamoto and French model to 
perfectly model human liver disease owing to alcohol. Finally, the intragastric 
model of ethanol is a chronic experimental model. When employing a chronic 
model of liver damage, it is often difficult to discern between effects and 
120 
proximate causes in chronic models of liver disease, suggesting that to fully 
determine the role of target in hepatic inflammation, an acute model of 
inflammation might be useful. 
There are acute models of inflammation such as an LPS sensitization 
model that cause similar pathology (e.g steatosis, inflammation and necrosis) as 
observed with the Tsukamoto and French intragastric ethanol model but the 
mechanisms behind liver injury owing to acute LPS exposure are less 
mechanistically complex than those of chronic ethanol. Therefore, it may be 
useful to determine the role of PKCE in hepatic inflammation owing to acute 
models of hepatoxicity like LPS or bile duct ligation for example. 
Chapter V determined that PKCE plays a critical role in hepatic fibrosis 
owing to chronic CCI4• The advantages of this model have been highlighted 
previously Chapter 1 (section E). The major drawback of this model is that it is 
irrelevant to human fibrosis. People do not consume CCI4 , nor can they survive 
transaminase values >8000 lUlL as witnessed in rodents chronically exposed to 
CCk Until recently, there have been no optimal rodent paradigms to model 
fibrosis in humans. Nevertheless as the PKCE ASO was able to partially blunt 
fibrosis caused chronic CCI4, which is considered to be a very severe model of 
fibrosis, it is likely that the ASO will confer a similar protective effect against a 
less robust model (e.g. angiotensin II) of fibrosis. Such a weight-of-evidence 
approach would be useful. 
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D. Future Directions 
1. Do other isoforms of PKC contribute to ALD? 
Future directions described here are to address issues mentioned in 
Weakness (Chapter 6, section C2). The purpose of these experiments is to build 
on the ideology of this dissertation and these future projects are not required to 
complete this dissertation. There are many isoforms of PKC that like PKC£, play 
a role in many processes hypothesized to be involved in ALD. For example, 
previous studies have shown that PKCa mediates collagen synthesis leading to 
lung fibrosis. 126 Whereas the investigation of individual PKC isozymes has been 
difficult due to non-selective inhibitors, small peptide inhibitors and ASOs are 
becoming more readily available to use in experimental settings. A recent study 
employed the use of an ASO, known as aprinocarsen, targeted against PKCa to 
determine the role of this PKC in tumorigenesis. 127 Mentioned previously, PKCa 
is known to coordinate collagen synthesis in the lung; it may also playa similar 
role in the liver leading to hepatic fibrosis. Therefore, a future study could 
investigate the role of PKCa in CCl4-induced fibrosis by employing aprinocarsen. 
2. Does PKCE playa role in angiotensin II-induced fibrosis? 
Recent unpublished work by Dr. Julianne Beier, a member of Dr. Arteel's 
lab, has resulted in the development of a new experimental model of hepatic 
fibrosis. Mice received angiotensin II for four weeks via an osmotic pump, 
resulting in "chicken-wire" fibrosis with little or no liver damage. This model is 
considered to be more relevant to human liver disease than pre-existing models 
(e.g. bile duct ligation, CCI4), as it causes mild fibrosis and relatively little liver 
122 
injury. Results from that study demonstrated that the fibrosis under those 
conditions is most likely due to an increase in stellate cell activation and an 
upgregulation of PAI-1, a similar mechanism by which PKC£ causes CCI4-
induced fibrosis. Therefore, it may be beneficial to determine if the PKC£ plays a 
critical role in angiotensin II-induced fibrosis. 
3. Does PKCE playa critical role in LPS-induced hepatic inflammation? 
The release of proinflammatory mediators from macrophages, especially 
Kupffer cells, is hypothesized to be a major mechanism involved in ethanol-
induced inflammation. In Chapter 1 (section D), it was stated that PKC£ primes 
macrophages to release proinflammatory cytokines due to LPS administration.6o 
Given this role of PKC£, it was unexpected that the PKC£ ASO was unable to 
prevent inflammation caused by chronic ethanol exposure (CHAPTER IV). 
However as mentioned in section C2 of this chapter, whereas the chronic model 
of intragastric ethanol exposure is very relevant clinically, it is very biochemically 
complex suggesting there may be a need to investigate the role of PKC£ in an 
acute model of inflammation. 
A previous study by this group determined that fibrin accumulation 
contributes to inflammation in a model of ethanol sensitization to LPS-induced 
liver damage.97 Under those conditions, it was proposed that pre-exposure to 
ethanol primes Kupffer cells to release TNFa caused by LPS. TNFa then 
activates PAI-1 via ERK1/2; PAI-1 then inhibits the plasminogen activating 
system leading to fibrin accumulation and the subsequent inflammation. In 
Chapter IV, results demonstrated that the PKC£ ASO, while able to attenuate the 
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upregulation of TNFa, was not able to prevent the increase in mRNA levels of 
PAI-1, suggesting that under those conditions PAI-1 is TNFa independent. In the 
study by Beier et al,97 TNFa indirectly upregulated PAI-1 which then causes fibrin 
accumulation and hepatic inflammation. As TNFa seems to be regulated by 
PKC£ (Figure 4.6A), the PKC£ ASO may confer protection against inflammation 
caused by ethanol/LPS by preventing the increase in TNFa mRNA levels and the 
subsequent upregulation of PAI-1. Future experiments could be completed to 
investigate this possible role of PKC£ in hepatic inflammation owing to a 'two-hit' 
model of ethanol and LPS. 
4. Are steatosis and inflammation mechanistically linked? 
One of the prevailing hypotheses in experimental liver research is the 
'two-hit' hypothesis, which implies that preventing the early stages of liver 
damage (i.e. steatosis) will result in the protection against later stages of ALD, 
thus suggesting that fatty liver is critical to the development of ALD.9, 128 
Therefore, it was very surprising that the prevention of steatosis by the PKC£ 
ASO did not correlate with protection against steatohepatitis (Chapter IV). These 
data therefore suggest that steatosis and inflammation owing to ethanol may not 
necessarily share a common mechanism. Described in more detail in Chapter IV 
(section E), such results showing the disconnect between steatosis and 
inflammation are not without precedence.97, 101, 103 A better understanding of this 
possible mechanistic detachment between fatty liver and inflammation is crucial 
in finding a viable therapy to treat ALD. 
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One possible explanation for the disconnect between steatosis and 
inflammation could be that a fatty liver is not a proximal cause of the sensitization 
of the liver to further insults that result in steatohepatitis but rather the 
development of fatty liver and inflammation may occur in parallel. Therapies may 
be blocking mechanisms, which results in protection against both early and late 
stages of liver damage. Therefore, it is plausible that in the chronic ethanol 
model, PKCE plays a causal role in the development of fatty liver, but not in 
sensitizing the liver to a second hit. Future experiments must be completed in 
order to better understand the 'two-hit' hypothesis to better understand its 
applicability to ALD. 
One of the findings of Chapter IV is that the PKCE ASO does not prevent 
hepatic inflammation due to fibrin accumulation via PAI-1 being independent of 
PKCE. Further studies by this group have also demonstrated that the inhibition of 
PAI-1 prevents LPS-induced hepatic inflammation, in the absence of steatosis, 
by blocking fibrin accumulation.97 Therefore, it could be possible that fibrin 
accumulation is a mechanism that occurs in parallel with steatosis to sensitize 
the liver to further damage as fibrin matrices are permissive to chemotaxis and 
activation of monocytes and leukocytes. 106, 107 This possible role of fibrin in 
sensitization could also explain other studies where a disconnect between fatty 
liver and inflammation has occurred. For example, the knockdown of DGAT2 
prevented steatotis but worsened inflammation in a methionine-choline deficient 
mouse model.101 The inability of DGAT2 to block inflammation coincided with 
elevalated hepatic free fatty acids. Importantly, free fatty acids have been shown 
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to prevent plasmin activation, leading to fibrin accumulation. 129 Therefore, the 
hepatic inflammation not blocked by DGAT2 could be owing to inhibition of 
fibrinolysis due to elevated fatty acids under those conditions. Therefore, it may 
be possible that therapies that block both steatosis and inflammation are doing 
so by attenuating fibrin accumulation and steatosis simultaneously. Further 
studies should be designed to test this hypothesis that the development of 
steatosis and fibrin-induced hepatic sensitization are occurring in parallel. 
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Figure 6.1: The involvement of other organs and cell types in causing ALD. 
This scheme illustrates the involvement of a multitude of different cell 







Figure 6.2: Working hypothesis by which PKCE causes ethanol-induced 
steaosis 
The increase in the pyridine nucleotide redox state caused by ethanol 
metabolism inhibits the p-oxidation of free-fatty acids (FFA). This increase in 
FFA leads to an increase in the flux through the DAG synthesis pathway. DAG 
activates PKCE, which then causes hepatic insulin resistance, by impairing the 
tyrosine phosphorylation of IRS1/2. The insulin resistance exacerbates the 
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Figure 6.3: The working hypothesis by which PKCE plays a critical role in 
hepatic steatosis but not inflammation or necrosis owing to chronic 
ethanol exposure 
Chronic ethanol causes a flux of free fatty acids into the DAG synthesis 
pathway, leading to increased DAG production. DAG activates PKCE when then 
indirectly upgregulates FAS via TNFa. FAS then synthesizes lipids (NEFA, TG, 
and phospholipids) leading to hepatic steatosis. Concomitantly, chronic ethanol 
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Figure 6.4: The proposed mechanism by which PKCE causes CCl4-induced 
hepatic fibrosis 
CCI4 causes fibrosis by first activating PKCE. PKCE subsequently 
upregulates the expression TGFJ31 , the major fibrogenic cytokine in the liver. 
TGFJ31 then activates hepatic stellate cells, which then increases fibrogenesis 
and impairs fibrinolysis (via PAI-1). 
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ABBREVIATIONS 
aSMA alpha smooth muscle actin 
ALD alcoholic liver disease 
ALT alanine aminotransferase 
ASO antisense oligonucleotide 
AST aspartate aminotransferase 
CAE chloroacetate esterase 
CCI4 carbon tetrachloride 
DAG diacylglycerols 
DGAT2 diacylglycerol acyltransferase 2 
EtOH ethanol 
FAS fatty acid synthase 
FFA free fatty acids 
GK glucokinase 
G6Pase glucose-6-phosphatase 
H+E hematoxylin and eosin 
IRS1/2 insulin receptor substrate 1/2 
MMP-9 metallomatrix proteinase 9 
NAFLD non alcoholic fatty liver disease 






plasminogen activator inhibitor 1 
protein kinase c-epsilon 
transforming growth factor beta 1 
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PRESENTATIONS 
1. Research Seminar, 03/06, "The effects of acute ethanol exposure on 
hepatic glucose regulatory genes" University of Louisville, Seminar in 
Pharmacology and Toxicology, Louisville, KY. 
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2. Poster Presentation, 10/06, "Metformin prevents the downregulation of 
GK caused by ethanol; critical involvement in steatosis?" University of Louisville, 
Research! Louisville, Louisville, KY. 
3. Research Seminar, 05/07, "The role of PKC£ in alcoholic liver disease" 
University of Louisville, Cytokines, Inflammation and Chemoprevention Group, 
Louisville, KY. 
4. Oral master's exam, 05/07, "The role of PKC£ in alcoholic liver disease" 
University of Louisville, Seminar in Pharmacology and Toxicology, Louisville, KY. 
5. Poster Presentation, 10/07, "PKC£ plays a causal role in ethanol-
induced steatosis" University of Louisville, Research! Louisville, Louisville, KY. 
6. Poster Presentation, 11/07, "PKC£ plays a causal role in ethanol-
induced steatosis" AASLD, Boston, MA. 
7. Poster Presentation, 12/07, "PKC£ plays a causal role in ethanol-
induced steatosis" James Graham Brown Cancer Center Retreat, Louisville, KY. 
8. Poster Presentation, 10/08, "PKC£ plays a critical role in CCl4-induced 
hepatic fibrosis in mice" Research! Louisville, Louisville, KY. 
9. Poster Presentation, 10/08, "PKC£ plays a critical role in CCl4-induced 
hepatic fibrosis in mice" James Graham Brown Cancer Center Retreat, Louisville, 
KY. 
10. Poster Presentation, 11/08, "PKC£ plays a critical role in CCl4-induced 
hepatic fibrosis in mice" AASLD, San Francisco, CA. 
11. Researcher Seminar, 04/09 "The role of PKC£ in alcoholic liver 
disease" University of Louisville, University of Louisville Alcohol Research 
Center, Louisville, KY. 
12. Researcher Seminar, 04/09 "The role of PKC£ in alcoholic liver 
disease" Loyola University Medical Center Alcohol Research Program, 
Maywood, IL. 
13. Researcher Seminar, 04/09 "The role of PKC£ in alcoholic liver 
disease" Institute for Biochemistry and Molecular Biology I, DOsseldorf, Germany. 
FELLOWSHIPS 
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Title: The role of PKCE in alcoholic liver disease; Agency: NIH (NIEHS); Type: 
Kirschtein institutional fellowship; Period: 09/01/2007-11/30/2007. Overall goals: 
Determine the role of PKCE in the early stages of alcoholic liver disease. 
Responsibilities: PI. 
Title: The role of PKCE in alcoholic liver disease; Agency: NIH (NIAAA); Type: 
Kirschtein individual fellowship; Period: 01/01/2008-01/01/2010. Overall goals: 
Determine the role of PKCE in the early stages of alcoholic liver disease. 
Responsibilities: PI. 
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